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ABSTRACT
In vitro multicellular spheroids are attractive model systems for assessing genetic and
epigenetic changes that occur in diseased tissues. Understanding how such alterations
in gene and subsequent protein expression affect disease progression and metastasis,
drug resistance, and recurrence is of great interest in cancer research. In this regard,
examining expression and activity of proteins, such as those with cytoprotective ability
that are overexpressed in cancer cells, in addition to cell phenotype (i.e., stem-like,
epithelial, mesenchymal, or mixed), are two ways to evaluate genetic and epigenetic
changes.

Moreover, determining the impact that cytoprotective proteins and cell

phenotype have on tumor formation would be beneficial to clinicians and drug developers,
as this would provide suitable targets for diagnostic testing and anti-cancer therapies.
One such cytoprotective protein is human NAD(P)H:quinone oxidoreductase-1 (NQO1),
due to its overexpression in diseased tissues. To this end, the goal of this research is to
determine if the expression and activity of NQO1 and cell phenotype in human tumorderived ovarian cancer cell lines influences in vitro spheroid formation. Therefore, in this
work will be detailed, characterization of four ovarian cell lines as a function of (1) NQO1
activity and expression in two-dimensional monolayers in addition to proliferative ability;
(2) spheroid formation under anchorage-independent culture conditions and subsequent
NQO1 expression and activity in said spheroids; and (3) the phenotype as determined
from presence of cancer stem cell markers and epithelial-to-mesenchymal transition in
monolayer and spheroid culture.

xv

CHAPTER 1
INTRODUCTION

1.1 Research Goals and Aims
Understanding ovarian cancer (OC) metastasis is crucial for the development of more
effective diagnostics and targeted therapies. More specifically, identifying factors that may
be aiding in its progression, chemo-resistant nature, and ultimately recurrence, is
significant. In this regard, taking a closer look at changes in expression and activity of
cytoprotective enzymes, as well as changes in the phenotypic nature of ovarian cancer
cells prior to and after treatment with chemotherapeutics, could be beneficial to clinicians.
Research of this nature could also be useful in understanding key features associated
with cancerous tissues like tumorigenesis and angiogenesis.
Human NAD(P)H:quinone oxidoreductase isozyme-1 (NQO1) is one cytoprotective
enzyme of interest. Primarily located in the cytosol, it catalyzes the two-electron reduction
of quinone substrates to hydroquinones.1 This process ensures that semiquinone radical
formation, which can be detrimental to the cells, is bypassed. Due to its overexpression
in several cancerous tissues (e.g., pancreatic, breast, lung, colorectal, and ovarian), both
its presence and activity toward substrates renders it beneficial for diagnostic testing and
chemotherapy.2-7 One such diagnostic technique is the use of NQO1-activatable
fluorescent probes, such as those developed in the McCarley research group, which
exploit the enzyme’s reductive abilities, allowing visual detection of NQO1 presence in
cancerous tissues.8-14 Moreover, the enzyme could also play a significant role in the
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formation, progression, and survival of solid tumors, thus again making it a target for
chemotherapeutics like -lapchapone ( -lap) and Mitomycin C (MMC).15-17
Aside from NQO1, research has shown that cancer cells can undergo phenotypic
transitions like those observed during embryonic development. Solid tumor tissues are
generally composed of cells with a more epithelial morphology, which is associated with
less invasive cells. In contrast, as the cancer starts to metastasize, the expression of
epithelial-associated biomolecules decreases, while increased expression of more
invasive, mesenchymal cells is found.16, 18-19 Mesenchymal cells are characterized as
having an elongated morphology, similar to fibroblasts, and increased motility, thus
allowing the cells to travel to distant sites within the body. It has been suggested that such
plasticity in cancer cells is driven by a population of cancer stem cells (CSC), which could
be controlling the adaptive nature of the cells prior to and after treatment. 20-21
My research goal is to investigate ovarian cancer tumorigenesis as a function of
oxidoreductase activity/expression and the cell phenotype. My first aim was to identify the
presence of NQO1 in ovarian cancer cell monolayers of different origin (i.e., location in
peritoneal cavity, stage of cancer, and treated/untreated) using traditional biochemical
techniques such as western blotting, immunocytochemistry/immunofluorescence
(ICC/IF), real-time quantitative polymerase chain reaction (RT-qPCR). After evaluating
enzyme expression, I went on to examine its activity using an established spectrometric
method which exploits its reductive capability. Furthermore, I used a novel near-infrared,
“ON-ON” fluorescent probe, Q3NTCY, developed by Dr. Zhenhua Shen during his time in
the McCarley research group, for the visualization of NQO1 in ovarian cancer cells in twodimensional and three-dimensional cultures. This probe offers the advantage of both the
2

probe and reporting moiety being fluorescent, but at different wavelengths. This quality is
significant because it allows for detection of unreacted probe, as well as the reporting
moiety that is released upon NQO1-initiated cleavage.
After determining expression and activity of NQO1 in cell monolayers, I then sought
to evaluate its influence on the ability of cells to form three-dimensional multicellular tumor
spheroid (MCTS) mimics under non-adherent culture conditions. By altering culture
conditions, I was able to work with a system that better mimics solid tumors within the
body, as cell monolayers are primarily composed of proliferating cells. MCTS offer the
advantage of providing a heterogeneous population of cells with layers of proliferating,
quiescent, or necrotic cells, each with differing levels of enzymatic expression and
activeness due to interaction with oxygen and other nutrients needed for survival. Using
this method would also highlight which cell lines can form spheroids under these
conditions, which could then be related back to NQO1 expression/activity in cell
monolayers. Moreover, due the cell lines being of different origin, it would allow them to
be further categorized based on their sphere forming abilities.
Finally, I evaluated the phenotypic nature of cell monolayers and MCTSs, which could
potentially be driven by the presence of cancer stem cells or stem-like cells. If CSC are
found to be present in populations of the studied ovarian cancer cells, they could be the
driving force behind chemoresistance, as well as phenotypic nature (e.g., non-invasive
vs invasive) of the cancer cell lines. It is possible that cells undergo phenotypic transitions
between 2D and 3D culture, which could yield more information about the behavior of
such cells within the body. The epithelial-to-mesenchymal transition (EMT) describes the
loss of cellular polarity and adherent nature observed in solid tumors and the emergence
3

of elongated cells with increased motility and invasive characteristics. 18-20, 22 It has also
been suggested that a hybrid subtype of cells exist that exhibit features related to both
epithelial and mesenchymal cells, indicating that these cells could be completely plastic
in nature.
1.2 Cancer and Statistics
Cancer is defined as uncontrolled proliferation of cells in the body, whose cellular
functions have been altered, thus causing them not to behave in the same manner as
normal cells. Cancer-related deaths account for more than double the amount caused by
AIDS, malaria, and tuberculosis, combined. In the United States, it is the second most
prevalent cause of death after heart disease. It is estimated that in 2018 alone, roughly
1.7 million new cancer cases will arise, and 609,640 cancer-related deaths will
occur.23-24 While one specific cause of cancer has yet to be identified, researchers
suggest that non-modifiable factors like genetics, hormones, and immune functions, as
well as lifestyle choices (e.g., smoking vs not smoking, body weight, and diet) all influence
disease onset and progression.25 Although it has been suggested that by altering one’s
lifestyle choices, roughly 50% of cancers can be treated, it is critical that researchers
identify ways to target and treat cancers related to changes at the cellular level.
In Figure 1.1 is a proposed mechanism depicting the spread of cancer in the body. It
suggests that DNA mutation occurs leading to the disease initiation, followed by
promotion, also referred to as clonal expansion, into the tissue, and finally
progression/metastasis, which signifies that invasion of other tissues has occurred.25 This
process is thought to be driven by cellular mutations brought on by the changes in the
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DNA or the cellular environment. Due to rapid proliferation, these mutated cells can then
begin to proliferate and eventually give rise to progenitor cells that can go on to produce
tumors.25 Tumors are defined as growths that are either benign or localized at certain
area in the tissues, or malignant, meaning that they can shed cells into neighboring
tissues and the blood stream.25-26 Malignant tumors can result in poor patient prognosis
and resistance to chemotherapeutics due to constant changes to the cells’ DNA. 25-26

Figure 1.1. The evolution of cancer from normal epithelium to metastasis.

1.2.1 Ovarian Cancer and Statistics
Currently only three of the four most common types of cancer in the U.S. (i.e., lung,
colorectal, and breast) affect both men and women. However, OC is ranked fifth in cancerrelated deaths in women and has the highest mortality rate of cancers involving the female
reproductive system. The American Cancer Society estimates that in 2018, over 22,000
women will have been diagnosed with OC, and over 14,000 women will die from it. 27
While it is more prominent in women over the age of 63, it is not uncommon for younger
women to develop the disease. One key reason ovarian cancer is so lethal is that the
disease is asymptomatic until it enters the advanced stages. Moreover, most cancers
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typically spread to distant sites through the bloodstream, but it has been found that
ovarian cancer metastasizes via clumps of shed cells in the peritoneal cavity, as
demonstrated in Figure 1.2.

Figure 1.2. Proposed pathway of ovarian cancer metastasis.

Ovarian cancer can be divided into three types: epithelial, germ cell, and sex cordstromal, with epithelial ovarian cancer being the source of roughly 90% of cases. 24
Epithelial ovarian cancer can further be split into four subtypes: serous, endometrioid,
mucinous, and clear cell—all of which are characterized as diseases with different
biological pathways, risks, and treatments.23-24, 27 Serous OC accounts for over 50% of
epithelial ovarian cancer cases. It has been shown to affect both ovaries, be highly
aggressive, undetectable at early stages, and linked to poor patient survival. 24 More
recently, it has been suggested that serous-grade ovarian cancer may originate in the
uterine tubes and then disseminate to the ovaries and other sites within the peritoneal
6

cavity.24, 28-30 Both mucinous and clear-cell carcinomas account for 6% of all OC cases
of epithelial origin, while endometrioid carcinomas account for 10%.24, 27 Endometrioid
and clear-cell carcinomas are thought to derive from the lining of the uterus, and mucinous
ovarian carcinomas from either the ovaries or the fallopian tube–peritoneal junction.24, 27
Aside from the epithelial subtype of OC, the two types of non-epithelial ovarian cancer,
namely, germ-cell and sex cord-stromal, account for only about 5% of ovarian cancer
cases.24 Germ-cell carcinomas are derived from eggs in the ovary and are more common
in younger women. On the contrary, sex cord carcinomas and stromal sarcomas are
associated with several different cells (i.e., Leydig cells, Sertoli cells, and granulosa), as
well as the tissues supporting the ovaries. Moreover, sex cord-stromal carcinomas are
prevalent in women over the age of 50.31 Because both types of non-epithelial ovarian
cancer are rare, it is difficult for clinicians and physicians to diagnose them in the early
stages. Furthermore, both are believed to be associated with hormonal and genetic
changes in the body, and symptoms vary from irregular bleeding to development of male
physical characteristics.32-35
1.2.2 Cancer Hallmarks and Metabolism
A simplified explanation of cancer’s onset and progression was provided in Section
1.1. In this section, a more detailed review of major hallmarks of cancer and its
metabolism will be provided. In 2000, Hanahan and Weinberg described cancer cells as
having defects in regulatory systems that control normal cell homeostasis and
proliferation.36-37 They went on to suggest that six alterations in a cell’s physiology result
in malignancy, including a growth signal autonomy, bypassing antigrowth cues, avoiding
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apoptosis, unrestricted proliferation, angiogenic switches, and finally invasion and
metastasis, as depicted Figure 1.3.36-37 Normal cells often take cues from the cell’s
microenvironment on when to undergo or halt mitosis. On the contrary, cancer cells have
been found be less dependent on these environmental cues, due to their ability to
synthesize their own growth factors. Moreover, due to overexpression of growth factor
receptors on the surface of cancer cells, it has been suggested that low levels of their
respective ligands can elicit a response leading to increased proliferation. In addition,
cancerous cells have been found to switch the type of cell surface receptors that are
expressed, which can lead to major changes in the way they behave.

Figure 1.3. The six hallmarks of cancer.
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Growth factor autonomy leads to cancerous cells being able to hijack certain signaling
pathways that govern transcription factors favoring antiproliferation. For example, the
retinoblastoma protein (pRb) is both a tumor suppressing protein and cell cycle regulator.
Hypophosphorylation of pRb alters the function of E2F transcription factors—major
contributors to cell cycle progression—resulting in cell cycle arrest and decreased
proliferation.37-38 However, cancer cells tend to block pRb’s influence on E2F genes
through several mechanisms, leading to enhanced proliferation.37-38 Aside from altering
cell cycle regulatory systems, cancerous cells can avoid apoptosis, or programmed cell
death. This evasion of apoptosis has been linked to decreased expression or mutations
in tumor suppressor gene p53. Also, overexpression and interaction of oncogenes like
BCL-2 and myc, led to antiapoptotic events in lymphomas and serum-deprived
fibroblasts.37, 39-40 Therefore, it is plausible that unrestricted proliferation in cancer cells
results in part from the combination of growth factor autonomy, bypassing antigrowth
cues, and evading apoptosis.
In normal cells, the amount of times cells can undergo division and replication to
produce a new progeny is often limited. Cellular senescence is the first barrier against
uncontrolled growth. It is the process by which proliferative ability ceases, yet the cells
remain viable.41 However, some cells can bypass senescence, resulting in the second
barrier—termed crisis—occurring, leading to widespread cell death. When viable cells
emerge from the crisis phase, they are considered immortalized as they have evaded cell
death.41 Studies have shown that cancer cells are considered immortal due to their ability
to bypass senescence and/or escape the crisis phase. 41-42 This ability has been largely
associated with increased telomere presence at the ends of chromosomes, essentially

9

protecting the DNA from erosion that could potentially lead to death.41-42 Therefore,
proliferative ability leading to the generation of a new progeny is dependent on the
telomeric presence. Cancer cells have been shown to exhibit increased telomerase, the
enzyme responsible for adding more telomeres to chromosomal DNA, activity and
expression not observed in normal cells.41
While the factors discussed above are key to cancer progression, angiogenesis—the
growth of new blood vessels—ensures that oxygen and other nutrients are constantly
supplied to tumors.36-37, 43 It has been shown that angiogenic-activators, like vascular
endothelial growth factor (VEGF) and fibroblast growth factors (FGF), are often found at
elevated levels in cancerous tumor tissues, while proteins that act as inhibitors of the two
are downregulated.36-37, 44 Expression of VEGF and FGFs allow tumor tissues to recruit
endothelial cells, which line blood vessels, thus giving them access to nutrients found in
the blood supply.45 Acquiring more oxygen and nutrients from the blood stream provides
cancer cells with support for their rapid metabolism, thus ensuring their survival and
synthesis of other nutrients.
However, tumors generally expand rapidly leading to slower diffusion of oxygen and
nutrients from the bloodstream, resulting in a hypoxic environment and stabilization of
hypoxia inducible factor (HIF).46-47 HIF induces the production of glucose transporters
(GLUT1 and GLUT2) and has been linked to angiogenesis by activating VEGF. 46-48 In
fact, this environmental shift favors glycolysis in lieu of aerobic respiration via the
mitochondria and was first described by Otto Warberg.49 However, it is important to note
that mitochondrial respiration still occurs, but the pathway is not as advantageous to
highly proliferative cancerous cells. Moreover, enhanced HIF expression is influenced by
10

both glycolysis and mitochondrial respiration, due to highly reactive species that lead to
stress being produced by both pathways.50-51 It has been suggested that tumors take
advantage of the hypoxic conditions, because they will lead to enhanced glucose
transport and consumption, as well as allow for more glycolytic intermediates to be
produced, thereby generating a wide variety of macromolecules essential for tumor
growth and development.43-45, 50 Also, glycolysis results in the formation of an abundance
of lactate, an anaerobic product of the pathway, regardless of the amount of oxygen
present. Increased lactate production is often counteracted by increasing the rate of
glycolysis—which again can lead to the production of more HIF.47, 50, 52
Another nutrient that is found at elevated levels in tumor cells is glutamine. Glutamine
is an essential amino acid involved in the synthesis of a variety of nitrogen-containing
compounds from nucleotides to non-essential amino acids.43 It has also been found to
have a role in the transport of essential amino acids including leucine, tyrosine, and
tryptophan to name a few. Due to their roles in biosynthesis of diverse nutrients needed
for survival and maintenance, it is not surprising that both glucose and glutamine have
been found to be overexpressed in tumorous tissues in comparison to normal tissues. It
has also been suggested that growth factors in nutrient-deprived cells and the ECM
enable increased uptake of glucose into cancerous cells.44, 52
1.2.3 Cellular Plasticity and Heterogeneity in Cancer
Cancer is a multidimensional disease. It arises from the various intrinsic and
extrinsic alternations that occur within and around diseased cells that lead to
heterogeneity and tumorigenesis. Moreover, these changes result in mixed populations
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of cells with varying degrees of tumorigenic potential. Intrinsic changes affect cellular
genetics, epigenetics, and influence which cells are capable of initiating tumorigenesis. 53
Genetic mutations have been implicated as driving forces in disease onset, progression,
and recurrence. It has also been shown that identifying mutant genes is beneficial for both
diagnostics and targeted therapies. For example, clinicians look for mutations in breast
cancer 1 or 2 genes (BRCA1 and BRCA 2, respectively) to diagnose early onset breast
cancer.53-54 Unlike genetic alterations, epigenetic changes that occur in cancer are not
the result of mutations or deletions in the DNA sequence, but instead are changes in what
genetic information manifests in cells, which is directly linked to the structure of
chromatin.55-59 This type of variability is associated with changes in level of DNA
methylation and modifications to histones and microRNA expression. Research has also
shown that epigenetic mutations have the potential to be reversed.
On the contrary, extrinsic factors, specifically the changes in the cellular
microenvironment that encompasses the extracellular matrix (ECM), blood vessels, and
supporting cells (i.e., fibroblasts and immune cells), impact the behavior of cancer cells.53
In cancerous tissues, changes in the microenvironment can lead to uncontrolled
proliferation, invasiveness, and act as a chemoattractant for stromal cells.60-61 It can also
be posited that changes within the microenvironment impact epigenetic aberration due to
the cell monitoring which genes are expressed when conditions surrounding it change.
Moreover, the notion of epigenetic modulation in response to changes in the
microenvironment suggests that both the intrinsic and extrinsic factors work together to
influence the aggressive phenotype exhibited by most cancers.
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1.2.4 Epithelial-to-Mesenchymal Transition (EMT)
In the last section, intrinsic and extrinsic alterations that affect the heterogeneity and
tumorigenic nature of cancer cells were introduced. One important concept was that
variations within the cell (i.e., genetic and epigenetic) and in the microenvironment
influence the phenotypic nature of the cancer cell, and ultimately metastasis. In recent
years, researchers have suggested that epithelial cells exhibit a high level of plasticity
and switch their phenotype in response to intrinsic or extrinsic cues. This phenomenon is
referred to as EMT, or epithelial-to-mesenchymal transition, which is an important process
in early embryonic development.18-19, 62 EMT refers to the loss of epithelial characteristics,
like cell-cell interactions and polarity, and the acquisition of mesenchymal characteristics,
including an elongated shape, like that of fibroblasts, and enhanced migratory ability as
depicted in Figure 1.4. In addition to EMT, the reverse reaction, the mesenchymal-toepithelial transition (MET) is also required.
In most cancers, this process is marked by the loss of or decreased expression of
epithelial markers (e.g., E-cadherin, occludin, and keratin) and increased expression of
mesenchymal markers, such as vimentin, N-cadherin, and vitronectin).63-64 In addition,
the transition between the two phenotypes is also associated with alterations in
expression of several transcription factors (e.g., Snail, Twist, Slug, and -catenin) and
activations of kinases (e.g., PI3K/AKT, NFB, and ERK 1 and 2).64-65 Moreover, increased
expression of collagen IV and fibronectin in the ECM has also been found to be related
to the occurrence of EMT.22, 64 It is when cells acquire a mesenchymal phenotype that
they start to exhibit more aggressive and invasive behaviors, and as a result, influence
cancer progression. Both pathways are needed for migration and invasion at distant sites,
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survival, and metastatic dissemination.18-19, 62, 65-66 Research has also shown that each
pathway increases cancer cell survival and induces resistance to anti-cancer agents.

Figure 1.4. Epithelial-to-mesenchymal transition (EMT).

1.2.5 Cancer Stem Cell Theory
The plastic nature of cancer cells is thought to be the result of a small population of
cells with stem-like qualities, dubbed cancer stem cells. Like normal stem cells, CSC can
self-renew, initiate tumor growth, and differentiate into progenies that may not exhibit
stem-like qualities.26, 53 Research on acute myeloid leukemia supported the CSC theory
in that cells with leukemia-initiating cells differentiated, proliferated, and regenerated in a
manner similar to that of hematopoietic cells.67-68 Traditionally, this hierarchy is referred
to as the CSC theory, which states that CSC can undergo either symmetric or asymmetric
division.53 Symmetric division would result in self-renewal; thus, all daughter cells would
be identical to the parent cells. Alternatively, asymmetric division would result in a
progeny composed of non-CSC with phenotypes that are modulated in part by changes
within the microenvironment. This small subset of CSC is believed to be the driving force
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behind tumor recurrence, drug resistance, and metastasis in cancer; even though nonCSC make up most established tumors.53
In recent years, researchers have suggested that the traditional CSC theory is not as
straightforward as previously presumed. Moreover, epigenetic changes can potentially
result in CSC shutting down genes associated with stemness and initiate lineagespecification genes. Considering the impact epigenetic change has on the behavior of a
given population of cells, the modified CSC theory posits that some non-CSC can
reacquire the CSC phenotype, thus suggesting that the pathway from CSC to non-CSC
is bidirectional.53 The new theory expands upon the idea that plasticity in cancer is an
attribute shared by both CSC and non-CSC. One instance of the modified CSC theory in
action involves transcription factor PAX5, which is required for the differentiation of
lymphoid progenitor cells. Once PAX5 was silenced, mature B-cells dedifferentiated back
to their progenitors.69-70 Moreover, it has been found that some non-CSC can acquire a
stem-like phenotype due to overexpression of oncogenes like the BMI1 polycomb ring
oncogene or oncogene fusion proteins, such as MOZ-TIF2 and MLL-ENL.71-73 Both CSC
models are displayed in Figure 1.5.

Figure 1.5. Models of the Cancer Stem Theory (CSC). (A) Traditional CSC theory
and (B) Modified CSC theory.
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Several molecules have been identified as CSC markers in cancer. Cluster
differentiation (CD) markers are a family of glycoproteins located on the cell surface with
roles in various cellular functions. While several CD markers have been suggested to be
involved with stemness, two of the most widely studied markers, CD133 and CD44, will
be highlighted. CD133, or Prominin-1, is a transmembrane protein found in human
hematopoietic stem cells and several cancerous tissues (colon, pancreatic, ovarian, and
gall bladder) with roles in tumorigenesis, metastasis, self-renewal, resistance, and
apoptosis.74-77 It has been found to be upregulated by both intracellular and extracellular
factors such as hypoxia, transforming growth factor 1 (TGF1), and microRNAs.56, 75-79
CD44 is a surface glycoprotein associated with a family of cell adhesion molecules
(CAM).64 It has been found to bind with ECM components like laminin and fibronectin,
cytokines, and a variety of growth factors, rendering it useful in cell signaling; thus, it is
not uncommon for CD44 to be overexpressed on the cell surface, particularly in
cancerous tissues.80-81 One of the key functions of CD44 is its role as a cell surface
receptor for hyaluronic acid (HA), which has roles in wound healing, immune response,
and blood vessel formation. Like CD133, CD44 has also been found to influence tumor
progression, metastasis, and resistance to anti-cancer agents.80, 82-83
Aside from CD markers, aldehyde dehydrogenase (ALDH), an enzyme involved in
cellular detoxification, has also been implicated as CSC marker.84-85 It has been found
that ALDH is linked to drug resistance, differentiation, and angiogenesis. It has been
found to be overexpressed in non-small cell lung cancer cells (NSCLC), yielding them
highly tumorigenic and capable of self-renewal.86 Epithelial cell adhesion molecule
(EpCAM) is a transmembrane glycoprotein that is expressed in both normal epithelia and
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stem cells. It has also been found to be heterogeneously overexpressed in cancerous
tissues. It has been identified as a CSC marker in breast, colon, and pancreatic cancers,
due to its roles in cell proliferation, differentiation, and signaling.87-90
1.2.6 EMT and CSC in OC
Earlier in the chapter, EMT and the CSC theory were introduced. However, this
section will focus specifically on EMT and CSC exhibited in OC. It has been found that
normal ovarian surface epithelium exhibits a mixed phenotype, being that it expresses
both epithelial and mesenchymal features. However, it is keratin, not E-cadherin, that is
prominently expressed alongside vimentin in these tissues.91

Also, N-cadherin, an

adhesion molecule associated a mesenchymal phenotype, has also been found to be
present in normal ovarian surface epithelia.92-93 Moreover, it has been shown that Ecadherin expression is increased in inclusion cysts and inner layers of epithelia, which
are areas where malignancy is thought to occur.64, 94 The assumption that E-cadherin
presence may be associated with diseased tissues was further supported by studies
showing that the marker had enhanced expression in primary ovarian neoplasms.64, 95
These findings suggest that initially, malignant tissues are composed of cells with an
epithelial phenotype, and as the cancer advances it is repressed in favor of a more
mesenchymal phenotype. The shift from a mixed phenotype in normal ovarian epithelia
to either primarily epithelial or mesenchymal in early or advanced staged malignancies,
respectively, suggests that EMT is significant feature of OC.
Moreover, it is postulated that phenotypic transitions in conjunction with the cellular
microenvironment influence the tumorigenic nature of OC cells. Ovarian cancer cells

17

exclusively expressing a noninvasive, epithelial phenotype with intact cell junctions could
form MCTS in non-adherent culture with or without ECM components.16 Conversely, cells
expressing the more invasive, mesenchymal phenotype became epithelial-like under
anchorage-independent conditions indicating MET took place.16 Moreover, those same
cells expressed a hybrid phenotype, with mesenchymal cells on the outer layer and
epithelial cells in the inner regions of the spheroids.16 The shifts in phenotype presented
in these studies support the claim that cancer progression, and ultimately metastasis, is
due to the cell’s ability to switch on or off certain gene expression in response to
environmental cues.
Aside from EMT, extensive research conducted to determine the role of CSC in OC
has led to a collection of putative molecules thought to define ovarian CSC.96 It has been
proposed that the aggressiveness of ovarian cancer is due to transformations and
dysfunction related to stem cells in the ovary due to isolated tumorigenic clones
differentiating to form in vitro spheroids despite tissue-specific differentiation being
arrested.97 Similarly, Cioffi et al. found that ovarian cancer cells possessing two distinct
biomarkers, CD133 and CXCR4, were capable of forming microtumors with high
efficiency.98 CD133 is a widely studied OC CSC marker due to its expression being linked
to tumor formation both in vitro and in vivo.96, 99-102 In addition to CD133, studies by two
independent research groups have shown that aldehyde dehydrogenase isozyme-1
(ALDHA1) to be a prevalent marker in ovarian cancer stem cells.102-103 In fact, the work
suggests that cells positively expressing both markers were highly tumorigenic and
promoted angiogenesis. Other markers that have been found to be present in CSC of OC
are CD44 and CD117, and like CD133 and ALDH, were found to be involved in tumor
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initiation and propagation in vivo.64, 84, 96, 102 In addition to tumor initiation, these markers
have been found to promote angiogenesis, and be involved in promoting resistance to
chemotherapeutic agents.
1.3 Reactive Oxygen Species (ROS) and Cancer
Reactive oxygen species (ROS) are defined as highly reactive oxygen free radicals
like superoxide (

) or hydroxyl (

), as well as non-radicals like hydrogen peroxide

(H2O2) or ozone (O3) that can be converted into radicals.104 Mitochondria and NAD(P)H
oxidase are major producers of ROS within the cell, while pollutants like smoke are
exogeneous ROS producers.105 At low levels, ROS can be beneficial for cell signaling
and protein regulation due to antioxidant response systems that help maintain a
homeostasis in the cell.105-106 However, excessive ROS has been linked to several
diseases, including cancer, diabetes, and cardiovascular disease.
Damage to DNA, proteins, and lipids is likely to be the result of oxidative stress brought
on by increased ROS. DNA damage, particularly mutations, resulting from ROS has roles
in carcinogenesis, tumorigenesis, angiogenesis and induction of a malignant phenotype
breast, lung, and colon cancer.46, 107 Also, it has been found that ROS signaling pathways
promote enhanced proliferation, invasion, and survival in cancerous cells. It has been
noted that the invasive behavior observed in breast cancer cells was due to the
accumulation of HIF1 resulting from increased ROS.107 Likewise, superoxide presence
in ovarian cancer cells led to increased proliferation and malignant tumor growth in vitro
and in vivo, respectively.108 Pancreatic cancer cells have been found to avoid apoptosis
due to the generation of ROS by NADPH oxidase isoform 4, thus making them highly
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resistant to chemotherapy.109 The role of ROS in drug resistance will be discussed later
in this chapter.
1.3.1 Antioxidant Response: Nuclear Factor Erythroid related factor-2 (Nrf2)
In the last section, ROS and the impact it has on cancer onset and progression was
introduced, as well as how cells have a system in place to regulate it. One way to combat
ROS is using transcription factors that initiate the production of antioxidants like
glutathione (GSH), ascorbic acid, and vitamin C.110 In addition, cytoprotective enzymes
whose purpose is to catalyze reactions that work to maintain homeostasis are also
essential in the fight against ROS. Nuclear factor erythroid-related factor-2 (Nrf2) is
responsible for inducing the transcription of several cellular detoxifying genes associated
with metabolizing enzymes and drug transporters.110 Moreover, it also regulates the
transcription of cellular detoxifying enzymes, like NQO1 and heme oxygenase (HO-1), as
well as key antioxidants, like glutathione.111 Aside from activating antioxidant genes, Nrf2
has also been found to have roles in anti-inflammation, as well as mitochondrial
biogenesis and autophagy.112-113 Literature states that Nrf2 expression is regulated by the
Kelch-like ECH-associated protein 1, Keap 1, which causes the degradation of Nrf2 in the
cytoplasm.110 However, when cells are under oxidative stress, the Keap 1-Nrf2 complex
is disrupted, resulting in Nrf2 translocation to the nucleus where it activates gene
transcription of antioxidant response elements (ARE).110 This process is depicted in
Figure 1.6.
In addition to oxidative stress, it has also been found that miRNAs and several other
transcription factors have some regulatory influence on this pathway. Studies have shown
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that miR-200a, which regulates Keap 1 gene expression, inhibits the interaction of Keap1
and Nrf2. Moreover, when there is increased expression of miR-200a, Keap1 expression
is decreased. In breast cancer cells overexpressing Nrf2, decreased tumor formation
under anchorage-independent conditions was observed. miRNAs have also been found
to target Nrf2 in oesophageal cancer and blood borne diseases, like sickle cell anemia
and lymphoma. However, miRNA-controlled regulation of Nrf2 is not apparent in all
cancers. In fact, it has been suggested that loss-of-function mutations in Keap 1 can also
disrupt the Keap 1-Nrf2 interaction, leading to hyper-activation of Nrf2, and thus enhanced
transcription of ARE. Epigenetic aberrations to Keap1, specifically hypermethylation,
have also resulted in enhanced Nrf2 presence in cells.

Figure 1.6. Oxidative stress disrupts the Keap1-Nrf2 complex, leading to nuclear
accumulation of Nrf2. Nrf2 then binds to ARE leading to the production of multiple
detoxifying enzymes.

Nrf2 has also been found to activate various genes that are associated with cancer
cell proliferation and death. Studies have shown that Nrf2 is capable of binding to the
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ARE region of the Notch1 gene, resulting in increased proliferation and an aggressive
phenotype.114 Nrf2 has also been found to be involved in EMT, due to E-cadherin binding
to it (i.e., Nrf2), thus preventing nuclear accumulation and subsequent ARE gene
transcription.115-116 However, when zinc-finger E-box binding homeobox 1 (ZEB1) is
upregulated during EMT, ZEB1 suppresses E-cadherin, leading to enhanced expression
of N-cadherin and other mesenchymal markers, and subsequently more Nrf2 activity. In
Figure 1.7 is depicted alternate mechanisms for Nrf2 accumulation in the nucleus as a
function of ZEB1 inhibition of E-cadherin and miR-200a acting on Keap1.

Figure 1.7. Nrf2 nuclear translocation by way of (A) ZEB1 inhibition of E-cadherin
and (B) miR-200a inhibition of Keap1.

1.3.2 Human NAD(P)H:Quinone Oxidoreductase Isozyme-1 (NQO1)
Primarily localized in the cytosol, NQO1 catalyzes the two-electron reduction of
quinones to hydroquinones in the presence of cofactor NAD(P)H to prevent the
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production of semiquinone radicals.116 Its active site is in a non-covalent binding pocket
for FAD between two identical monomers. To be specific, when cofactor NAD(P)H is
present, NQO1 will bind to it, and hydride transfer will occur from NAD(P)H to the FAD+
housed in the active site of the enzyme yielding NAD(P)+ and FADH, respectively. FADH
will then donate a proton to a bound quinone substrate, thereby reducing it and
reestablishing the oxidized FAD. Because NQO1 has two identical active sites, this
process occurs twice. Figure 1.8 illustrates this process.

Figure

1.8.

NQO1

reduction

of

quinones

to

hydroquinones.

NQO1 is described as a protective agent within the cells, owing to its acting against
oxidative stress and neoplasia.1,

116

NQO1 also has bioreductive functions, such as

converting DNA alkylating quinones into highly cytotoxic species resulting in the
development of antitumor drugs.15 Two of the most notable DNA alkylating quinones,

-lap and MMC, which can be converted into highly cytotoxic species upon reaction by
NQO1, have been exploited in several studies.7, 17, 117 For example, -lap has been shown
to reduce inflammation and neoplasia, as well as act as an analgesic.17 Several groups
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have worked to several additional anticancer agents like indoloquinone EO9 and
Diaziquone (AZQ), which can also act as substrates that exploit the enzyme’s
bioreductive properties.118 In addition, NQO1 serves as a superoxide scavenger, as well
as a stabilizer of tumor suppressor genes.119-121 Other functions of the enzyme include
protection of proteins from 20S proteoseomal degradation, acting as a mRNA binding
protein, and being involved in the plasma membrane redox cycling process.116
Despite its detoxification and bioreductive properties, NQO1 has been found to be
overexpressed in several cancerous tissues.3, 5, 7, 122 Cui and colleagues found that poor
prognosis in advanced stage serous ovarian carcinomas was associated with elevated
levels of NQO1 in tumor tissues.4 Due to its increased expression in the initial stages of
ovarian cancer, NQO1 may be aiding in the progression of the disease rather than
preventing it.4 In another study, high NQO1 expression was associated with
tumorigenesis in NSCLC cells because upon repression of the enzyme, cells proliferative
and tumorigenic abilities decreased.123 Moreover, NQO1 inhibition was found to be
accompanied by increased ROS, which as mentioned in an earlier section, could result
in increased glucose metabolism and angiogenesis due to HIF being overexpressed.
1.3.3 NQO1-Activatable Fluorescent Probes
Due to its role in combating oxidative stress, as a bioreductive agent, and more
recently as a poor prognostic factor in cancer, NQO1 has been found to be an excellent
therapeutic target. In addition, the enzyme is overexpressed 5- to 200- fold in cancerous
tissues in comparison to neighboring tissues of solid tumors derived from lung, breast,
and pancreatic cancers.2, 6, 17, 123-124 Several groups have worked to develop anticancer
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agents like MMC, -lap, indoloquinone EO9 and AZQ, which act as substrates that exploit
the enzyme’s bioreductive properties. Overexpression of NQO1 has also rendered it an
excellent target for fluorescence-guided visualization of cancer, which is of great interest
to the McCarley research group. The McCarley group has synthesized several
fluorescently-silent probes equipped with quinone species serving as NQO1 substrates.
These probes become activated via reduction of the quinone substrates by NQO1,
leading to the release of highly fluorescent reporting moieties with emissions in the visible
and NIR regions of the electromagnetic spectrum. Scheme 1 is a generic depiction of the
proposed mechanism of NQO1 activation of fluorescent probes. Using this technology,
the McCarley lab has successfully distinguished between NQO1-postive and negative
cells and/or tissues via fluorescence microscopy with high target-to-background ratios
(TBR). To date, these highly specific and selective NQO1-activatable probes have been
used to visualize enzyme localization in human colon, pancreatic, lung, and ovarian
cancer cells.8-14 A complete list of developed NQO1-activable probes produced in the
McCarley lab is provided in Table 1.1.

A

B

C

D

Scheme 1.1. (A) Fluorescently-silent probe is reduced by NQO1 in presence of NADH
to from a (B) hydroquinone, which can then undergo lactonization to produce (C)
lactone and (D) fluorescent reporter.
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Table 1.1: NQO1-activatable probes developed in the McCarley lab
Probes

Application

O
H
N
O

H
N

O

O

O
N
O

Fluorescence detection of 5×10-5
g NQO1 in aqueous solution.13

O
O

O

O

N

O

Visualization of NQO1 activity via
fluorescence
microscopy
in
human carcinomas of various
origins.14

O
O

N

NH
O

O

COOH

O

O

N+

O
N

Visualization of NQO1 activity via
fluorescence
microscopy
in
tumor-derived human NSCLC and
colorectal cells.10

O

O
H
N
O

O

NH2

Visualization of NQO1 activity via
fluorescence
microscopy
in
tumor-derived human colorectal
and ovarian cancer cells.8

O
O
O

(Table cont’d.)
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Probes

Application

O

O

N

O

N
O

O

O

Visualization of NQO1 activity via
fluorescence
microscopy
in
tumor-derived human NSCLC and
colorectal cancer cells.9

NH
O

O

O

N

O

Visualization of NQO1 activity via
fluorescence
microscopy
in
tumor-derived NSCLC, colorectal,
and ovarian cancer cells.11

O
NH

N

O

O
O
O

Visualization of NQO1 activity via
fluorescence
microscopy
in
tumor-derived NSCLC, colorectal,
and ovarian cancer cells in vitro
and ovarian cancer in vivo.12

S
O
O
NI+-

N
N

1.3.4 Additional Cytoprotective Enzymes
In addition to NQO1, Nrf2 translocation to the nucleus and subsequent transcription
produces several other cytoprotective enzymes. One of these is heme oxygenase-1 (HO-
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1), whose role in ROS, cell growth, and chemoresistance has been widely studied.111 HO1 is responsible for catalyzing the oxidation of heme into ferritin, biliverdin/bilirubin, and
carbon monoxide.110-111 While the first two products of this process are antioxidants,
carbon monoxide has antiapoptotic properties. HO-1 is present in low levels in the cell
unless its expression is induced by stressors. It is considered as a major effector of
cellular responses mediated by Nrf2. Moreover, like NQO1, HO-1 has been associated
with aggressiveness, survival, and poor prognosis in several cancers. 125-128 It has also
been linked to resistance to chemo- and radiation therapies.128-129 Also, it has been found
that if the enzymes expression is inhibited, cancerous tissues become sensitive to
therapy.127, 130
Nrf2 is also responsible for the transcription of enzymes required for de novo synthesis
and redox homeostasis of glutathione (GSH), which has been described as one of the
most important antioxidants in the body. More specifically, Nrf2 regulates the transcription
of glutathione reductase, which is responsible for reducing oxidized glutathione (GSSH)
to GSH, thereby modifying GSH redox state.110 GSH modulates cellular redox signaling,
proliferation, and death. Like HO-1 and NQO1, GSH works to remove toxic ROS and
reactive nitrogen species (RNS) from the cell to maintain homeostasis. GSH is also
involved in recycling other antioxidants as well as acting against inflammation. 112 It serves
as

a

cofactor

for

gluthathione

peroxidases,

gluthathione-S-transferases,

and

glutaredoxins; all of which are antioxidant enzymes.110 However, glutathione levels have
been found to increase in cancer cells after treatment with chemotherapeutics. Godwin
and colleagues observed that ovarian cancer cells with a wide range of resistance to
cisplatin also had increased levels of GSH compared to parental cell lines.131 In the same
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study, it was found that enzymes involved in the synthesis of GSH showed increased
expression in highly cisplatin-resistant cells.131
1.4 Treatment, Resistance, and Recurrence
While surgery and radiation treatment are often the first lines of defense, not all tumors
are amendable to them, due to some of the diseased tissue still being present after
treatment. As a result, several systemic drugs like cisplatin, paclitaxel, and doxorubicin,
to name a few, are employed. However, the use of anti-cancer drugs is correlated with
two forms of resistance: intrinsic and acquired. Intrinsic resistance is observed in patients
that do not display sensitivity to anti-cancer therapy after initial treatment, whereas
acquired resistance manifests in patients that were once sensitive to therapy but become
resistant to it overtime.53 Intrinsic resistance is thought to be the result of genetic changes,
such as mutations in genes associated with growth factors, oncogenes, cytokines, and
signaling pathways. For example, mutations in tumor suppressor gene p53 were found to
be associated with resistance to cisplatin and doxorubicin in NSCLC and breast cancer,
respectively.132-133 Regardless of the form of resistance, it is important to understand the
changes occurring within the cells remaining after initial treatment.
Mounting evidence suggests that acquired drug resistance is due in part to EMT taking
place in cancer cells, thereby leading to the development of metastatic disease.21 Several
studies have demonstrated that cancerous cells of epithelial origin are often sensitive to
anticancer agents; however, acquisition of a mesenchymal phenotype has been linked to
increased resistance. This was evident in studies where transcription factors Snail and
Slug, which induce EMT, were all upregulated in cells showing resistance to cisplatin in
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lung, head and neck squamous, and ovarian cancer cells.71, 134-136 Moreover, researchers
found that after repressing both transcription factors, the cells became re-sensitized to
the drug. Silencing of Snail resulted in tumor and immunosuppression melanoma and
induced apoptosis in an Adriamycin-resistant melanoma.137
Resistance and subsequent recurrence are thought to be the result of tumor
dormancy, a period after initial treatment where proliferation is halted, and cells lie in a
state of mitotic arrest. Dormant cells are believed to be CSC capable of inducing EMT,
which then circulate locally or through the bloodstream to distant sites where they will
later invade.138 Because they can survive in a highly stressed environment, these cells
are considered highly resistant to chemotherapy. Resultantly, EMT and CSC are often
studied in tandem, due to phenotypic transitions occurring in diseased cells resulting in
the acquisition of epithelial, mesenchymal, or a mixture of the two along with stemlike
features during relapse.64, 138 For example, circulating tumor cells have been found to
exhibit behaviors mirroring cells undergoing EMT as well as CSC.138 A study by Mani and
colleagues supports EMT and CSC being studied together.139 The work details how
breast cancer cells overexpressing EMT- promoting transcription factors, snail and twist,
were found to also highly express CSC marker CD44.21,

139

Moreover, these cells

exhibited a malignant phenotype and could produce mammospheres in vitro.
1.4.1 Cisplatin Resistance
The remaining section will focus on reviewing specific genetic and epigenetic
aberrations that occur after initial or prolonged exposure to the chemotherapeutic drug
cisplatin. Treatment with chemotherapeutics in ovarian cancer often results in acquired
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resistance after initial exposure as evident by over 70% of women experiencing
recurrence 6-18 months after initial treatment.140-142 Research suggests that mutations in
genes like p53, which is linked to DNA repair and cellular apoptosis, may be involved in
acquired resistance to chemotherapeutic drugs.132 Furthermore, Perego et al. found that
resistance to cisplatin in ovarian cancer is linked to mutations in the p53 gene that inhibit
its ability to activate bax, an apoptotic gene.143-144 Likewise, research conducted by Parker
et al. and Masuda et al. suggests that cisplatin resistance in OC is associated with
increased DNA repair of lesions and decreased drug accumulation.145-146
Aside from altering the rate at which DNA lesions are repaired and reducing overall
drug accumulation, drug resistance, particularly resistance to cisplatin has been found to
be linked to several other genetic and epigenetic changes within cells. Extensive research
has been conducted to probe the effect that cisplatin has on diseased tissues. It has been
associated with endocytic defects, which can be linked to reduced uptake of the
drug.147-148 Other studies have shown that cisplatin resistance is related to heat shock
proteins (HSPs), which work to ensure that cells are protected against DNA damage and
apoptosis resulting from an influx of oxidant species.144 It has been suggested that the
upregulation of HSPs in cisplatin resistant cells could mean cell defense reactions may
be comprised.144 Research has shown that ovarian, breast, and colon cancer cells, with
established resistance to cisplatin, have increased expression of several heat shock
proteins.149-151 Epigenetic alterations like enhanced chromatin condensation, DNA
hypermethylation resulting in gene silencing, and increased histone acetylation have all
been suggested to be associated with cisplatin resistance.144, 152-154
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Furthermore, several transcription factors have been linked to increased resistance to
cisplatin and other anti-cancer therapeutics. Some of these include activating
transcription factor 4, zinc-finger factor 143, nuclear transcription factor-B, mitochondrial
transcription factor A, and CCAAT-binding transcription factor 2.144 Another transcription
factor, p300/CBP-associated factor (PCAF), whose function is to initiate cell cycle arrest
and/or apoptosis via regulation of p53, p73, and BAX, has been shown to be
overexpressed in cisplatin resistant P/CDP6 and Hela/CP4 cells.155 It is also involved in
acetylating and stabilizing transcription factors E2F1 in response to DNA damage,
meaning it could be aiding in cellular survival in cells that overexpress it. In addition to
PCAF, Nrf2 and the cytoprotective genes (e.g., NQO1) it transcribes, have also been
linked to cisplatin resistance.15, 111, 156-157
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CHAPTER 2
EVALUATION OF NAD(P)H:QUINONE OXIDOREDUCTASE ISOZYME-1
EXPRESSION AND ACTIVITY, AND CELLULAR PHENOTYPE IN
HUMAN OVARIAN CANCER CELL MONOLAYERS
2.1 Introduction
Increasing evidence has been found suggesting that major detoxification pathways
may be involved in cancer progression, chemoresistance, and ultimately recurrence. As
detailed in Chapter 1, the Keap1/Nrf2/ARE pathway drives the production of
cytoprotective enzymes and antioxidants in response to oxidative stress. 1 However,
aberrant mutations in the genes that regulate this pathway can lead to overproduction or
underproduction of detoxifying proteins.1 In addition, it has been suggested that
abnormalities in this pathway can result in increased ROS, drug resistance, and even
tumor formation.2-5 Thus, assessing the level of influence cytoprotective proteins
associated with the Keap1/Nrf2/ARE pathway have on cancer progression and survival
is would beneficial to cancer researchers and clinicians.
One way to probe the influence of detoxifying pathways on cancer progression and
resistance is to monitor expression and subsequent activity of the cytoprotective species
that are generated as a result of it. NAD(P)H:quinone oxidoreductase isozyme-1 (NQO1),
a cytoprotective enzyme whose generation is directly influenced by the Keap1/Nrf2/ARE
pathway, has garnered attention due to its detoxifying and bioreductive capabilities within
the cell.6 As mentioned in Chapter 1, NQO1 combats ROS brought on by changes in the
cellular environment by ensuring that semiquinone radical production is minimized. 6 In
Scheme 2.1 is illustrated the reduction of 1,4-benzoquinone by a one-electron
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reductase (A) and NQO1 (B). Moreover, it has been found to be involved in generation
of antioxidants such as ubiquinone and vitamin E.

Scheme 2.1. Reduction of quinone by reductases. (A) Reduction by a one-electron
reductase (e.g., cytochrome p450) in the presence of NAD(P)H cofactor yields a
semiquinone radical. (B) Two-electron reduction of the quinone species by NQO1 in
the presence of NAD(P)H cofactor enables A to be bypassed, thereby yielding a
hydroquinone.

Unfortunately, NQO1 expression and activity provides benefits to both healthy and
diseased cells. The 2-electron reductase has been found to be highly expressed, up to
200-fold, in pancreatic, colorectal, lung, breast, gastrointestinal, and ovarian cancer tumor
tissues, in comparison to their normal counterparts.7-12 These findings have led to a surge
in anti-tumor drugs that are bioactivated by NQO1 to produce highly toxic species that
can combat disease.13-15 In addition to anti-tumor drug development, diseased cell
imaging strategies based on NQO1 reduction of quinone-based agents have become
extensive since the pioneering work of the McCarley group. The LSU team has created
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NQO1-activatable fluorescent probes that enable visualization of diseased tissues
overexpressing the enzyme, over a broad range of emission energies.16-23 Such probes
enable active NQO1 to be observed in live and subsequently fixed cells upon reduction
of a quinone probe substrate that leads to the release of a highly fluorescent reporter,
thus enabling visualization of NQO1-bearing cancer cells with confocal or widefield
microscopies.
To gain knowledge concerning NQO1 expression and activity levels in often-studied
ovarian cancer cell lines derived from patients at various disease and treatment timelines,
NQO1 expression and activity was examined in several high-grade serous ovarian
carcinoma (HGSOC) cell lines using traditional biochemical techniques and a NQO1activated fluorescent probe, Q3NTCY, developed by former McCarley group member, Dr.
Zhenhua Shen.24 In addition, culture time-dependent analysis of cellular proliferation,
which is likely to affected by both the presence and activeness of NQO1, as well as the
level of invasiveness of a cell line, was assayed.
2.2 Experimental
2.2.1 Cell Culture
Human ovarian carcinoma cell lines OVCAR-5, OVCAR-8, and SHIN-3, gifts from Dr.
Hisataka Kobayashi at the United States National Institutes of Health, National Cancer
Institute, Center for Cancer Research were used for the studies presented in this chapter.
Human ovarian carcinoma cell line OVCAR-3 was purchased from American Type
Culture Collection (ATCC). All cell lines were cultured in either DMEM or RPMI-1640
medium purchased from the ATCC, which was supplemented with 10% fetal bovine
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serum (FBS; ATCC), 10 IU/mL penicillin, and 10 g/mL streptomycin (Life Technologies),
unless stated otherwise. Bovine insulin (1 g/mL) was an additional supplement for
OVCAR-3 cells. Cells were cultured in 75 cm2 treated tissue culture flasks at 37 °C under
5% CO2 in a humidified incubator.
2.2.2 Protein Quantification
To determine the total protein concentration in cell monolayers for each cell line, bulk
protein was extracted. Briefly, cells were grown in treated tissue culture 6-well plates
(Fisher Scientific), and each day over a 7-day period, cells were dissociated with trypsinEDTA (Fisher Scientific). Following centrifugation at 900 rpm for 7 minutes at 4 °C, the
supernatant was removed, and 300 L of radioimmunoprecipitation assay (RIPA,
ThermoFisher) buffer with 1 mM phenylmethylsulfonyl fluoride (Sigma) and protease
inhibitor cocktail (Sigma) were added to pelleted cells. The suspended cells were
incubated on ice for 20 minutes with periodic vortexing to achieve homogeneity within the
solution. The solution was then centrifuged at 18,000 × g for 20 minutes at 4 °C. The
supernatant was obtained and aliquoted into sterile Eppendorf tubes at −80 °C until use.
Total protein content was quantified using the well-established BCA assay.
2.2.3 Western Blot
NQO1 expression was measured in 25–30 g protein samples, each
corresponding to the number of days that cells were cultured prior to protein extraction.
Samples

were

analyzed

using

sodium

dodecyl

sulphate-polyacrylamide

gel

electrophoresis (SDS-PAGE) using 4–20% polyacrylamide gels (Bio-Rad). 10 L of
Kaleidoscope Pre-Stained Standard marker was used to track proteins. Samples were
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diluted in 2X Laemmli sample buffer containing 2-mercaptoethanol at a 1:1 ratio. Protein
separation was conducted at 100 V for 65 minutes in running buffer (1X Tris/Glycine/SDS
in deionized water) followed by protein transfer onto nitrocellulose membranes in transfer
buffer (1X Tris-Glycine and 20% methanol).
Following transfer, the nitrocellulose membrane was blocked with 5% non-fat dry milk
(NFDM) for one hour before being washed with tris-buffered saline with 0.1% tween-20
(TBST) solution. Simultaneously, working concentrations of the mouse anti-NQO1
monoclonal antibody and rabbit anti--actin monoclonal antibody were added to each
membrane. All antibodies used in this work were purchased from Cell Signaling
Technologies. Upon antibody addition, membranes were incubated overnight at 4 °C with
gentle shaking. The following day, the membrane was washed with PBS 3X in 10-minute
intervals. Next, both anti-mouse IgG and anti-rabbit IgG, HRP-linked secondary
antibodies (Cell Signaling Technologies) were added to the membranes for 1 hour at
room temperature with gentle shaking. All antibodies were made at a 1:1000 dilution in a
1% NFDM. Super Signal West Pico Plus chemiluminescent substrate (Fisher Scientific)
was prepared based on the manufacturer’s protocol, and it was slowly pipetted onto the
membranes several times over a period of roughly 2 minutes. Membranes were imaged
using a Bio-Rad ChemiDoc MP system with an exposure time of 300 seconds at 60
second intervals. Raw images were saved in tagged image file format (TIFF) files, and
band analysis was performed using Fiji/ImageJ software.
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2.2.4 RNA Purification and Real-Time Quantitative PCR (RT-qPCR)
Total RNA from cell lines was extracted and purified for analysis using Direct-zol RNA
MicroPrep kit (Zymo Research) according to the manufacturer’s instructions. RNA was
quantified spectrometrically using an Epoch microplate reader (BioTek). Total RNA was
reversed transcribed to cDNA using TaqMan Reverse Transcriptase reaction mix
provided in the High Capacity RNA-to-cDNA Kit (Applied Biosystems) according to the
supplier’s instructions. The cDNA was diluted 1:10 in nuclease-free water and 2 L was
used as a template to perform RT-PCR in a 25 L reaction. -actin was used as an
endogenous control (Applied Biosystems, UK) in single-plexed PCR reactions on an ABI
ViiA-7 (qPCR) Detection System (Applied Biosystems) with fast thermocycling conditions
(50 °C for 2 minutes, 95 °C for 2 minutes, then 40 cycles at 95 °C for 1 second and 60 °C
for 20 seconds), using Taqman Fast Advanced PCR Master Mix (Applied Biosystems).
To confirm the modulated expression of the selected target gene and endogenous
control, TaqMan 20x gene expression primers and probes (Applied Biosystems) for
NQO1-Hs00168547_m1 and ACTB-Hs99999903_m1 were used. All PCR reactions were
performed in triplicate.
2.2.5 NQO1 Activity via Spectrometric Analysis/Enzyme Kinetics
NQO1 activity was assayed spectrometrically by measuring the absorbance at 600
nm

for

the

dicoumarol-sensitive

reduction

of

the

quinone

substrate

2,6-

dichlorophenolindophenol (DCPIP). The assay buffer consisted of 200 M NADH and
0.014% BSA in 25 mM of Tris-HCl at pH 7.4 with or without 20 M dicoumarol, a known
NQO1 inhibitor. A fraction of lysate was added to 0.75 mL of assay buffer to give a final
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protein concentration of 5 g in a 2-mL plastic cuvette. To start the reaction, 0.75 mL of
80 M DCPIP in assay buffer was added, bringing the final volume to 1.5 mL. Enzymatic
activity was determined based on NQO1 ability to reduce the DCPIP substrate at 600 nm
in the presence and absence of the dicoumarol inhibitor. Each measurement was carried
out using a Cary 50 UV/Vis spectrometer over a 2 to 10-minute timeframe depending on
the cell line being assayed. Dicoumarol-sensitive NQO1 activity is then calculated by
subtracting the activity of an assay with dicoumarol from the corresponding assay without
dicoumarol. Finally, activity is recorded in units of nmol /mg/min.
2.2.6 Immunocytochemistry/Immunofluorescence (ICC/IF)
OVCAR-5, OVCAR-8, SHIN-3, and OVCAR-3 cell monolayers were cultured overnight
in a 16-well chambered slide (LabTek) at 37 °C. The following day, cells were washed
with ice cold PBS for 5 minutes to remove excess media. Samples were then treated with
200 L of cold 4% PFA for 15 minutes in the dark at room temperature. Once the fixation
step was completed, samples were washed with PBS for 5 minutes. Samples were then
permeabilized with 1% PBST for 15 minutes at 37°C. 200 L 3% BSA blocking buffer was
prepared in PBST and added to each well. The slides were then incubated for 1 hour at
room temperature. Simultaneously, a working concentration mouse anti-NQO1 primary
antibody was prepared in 1% BSA in PBST at 1:200 dilutions. The antibody solution was
added at the volume of 200 L per well. The slides were incubated at 4 ºC for 1 hour with
shaking. Next, the primary antibody solution was removed, and samples were washed
with PBST 3 times for 10 minutes each. The secondary antibody was prepared in 1%
PBST solution. AlexaFluor-488 conjugated anti-mouse antibody (ThermoFisher) and
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prepared at 1:500 dilutions. The samples were incubated with secondary for 1 hour at
room temperature, after which they were washed 3 times with PBS. The separating
chamber and polymer coating were then removed from the slides and they were mounted
with ProLong Gold Diamond Anti-fade mountant with DAPI for nuclear colocalization
(ThermoFisher).
Stained cells were excited at 488 nm or 633 using white light laser with spectral
emission collected between 495-520 nm and 650-750 nm, respectively. The pinhole was
set at 1 Airy Unit (53.1 m). The DAPI nuclear stain was excited at 405 nm by an argon
laser with spectral emission collected between 410-483 nm. Each image was frame and
line averaged 4 and 2 times, respectively, at a scan speed of 8000 Hz. An Apo plan 20X
0.3 NA objective was used. Image analysis was performed using LAS X and Fiji/Image J
software.
2.2.7 Visualization of NQO1 Activity via Fluorescent Probe Q3NTCy
OVCAR-5, OVCAR-8, SHIN-3, and OVCAR-3 cells at a concentration of 2 × 105
cell/mL were cultured overnight onto 22 × 22 mm sterile glass coverslips (Corning) in
treated tissue culture 6-well plates containing RPMI-1640 medium supplemented with 10
% FBS, 10 IU/mL penicillin, and 10 μg/mL streptomycin. The following day, cell media
was removed, and cells were washed with PBS before warmed RPMI-1640 medium
without phenol red was added to each well. A 5 M concentration of Q3NTCy probe was
added to each well and incubated at 37 °C for 20 minutes. Following probe exposure, the
culture medium was removed, and cells were washed with PBS 3X before 2 mL of 4%
PFA was added to the wells. After fixation, cell-coated coverslips were then bonded to
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Colormark Plus Precleaned Microscope Slides with ProLong Gold Antifade mountant with
DAPI (ThermoFisher). Slides were left to dry overnight in the dark at room temperature.
Confocal images were collected using a Leica TCS SP8 laser-scanning confocal
microscope. The TCy reporter that was released from the Q3NTCy probe upon exposure
to NQO1 was imaged using a white light laser. The TCy reporter was excited at 633 nm
with spectral emission was collected between 650–750 nm using hybrid detectors. The
pinhole was set at 1 Airy Unit (53.1 m). The DAPI nuclear stain was excited at 405 nm
by an argon laser with spectral emission collected between 410-483 nm. Each image was
frame and line averaged 4 and 2 times, respectively, at a scan speed of 8000 Hz. An Apo
plan 20X 0.3 NA objective was used. Image analysis was performed using LAS X and
Fiji/Image J software.
2.3 Results and Discussion
2.3.1 NQO1 Expression in OC Monolayers
OVCAR-3, OVCAR-5, and OVCAR-8 cells were preselected for this study due to it
being shown that they more closely reflect the behavior of HGSOC.25 SHIN-3 cells are
not as common as the previously mentioned cell lines but were derived from an ovarian
serous cystadenocarinoma.26 It was also important to note that the patients from which
these cells were obtained may or may not have underwent chemotherapy prior to
debulking surgery, which could have an effect on the presence of NQO1. In addition, it
has been reported that OVCAR-3 cells were NQO1-expressing, however, its expression
in relation to that of other cell lines has yet to be determined.27-28 Therefore, NQO1
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expression in these cell lines was assessed using traditional western blotting, ICC/IF, and
RT-qPCR on monolayer cultures of each cell line.
Western blot analysis of cell monolayers (Figure 2.1.A) revealed that NQO1
expression was effectively undetectable in OVCAR-8, and only faint expression was
observed in OVCAR-3 cells. These findings were in stark contrast to those of OVCAR-5
and SHIN-3 cells, which showed expression of the enzyme. ICC/IF was incorporated to
qualitatively observe localization of enzyme. ICC/IF analysis, to an extent, corroborated
results from western blot analysis. Each cell line displayed expression of NQO1, with
OVCAR-8 cells yielding the lowest fluorescence intensity (Figure 2.1.B). However, the
fluorescence intensity of stained OVCAR-3 was comparable to that of OVCAR-5 and
SHIN-3. The lower overall expression of NQO1 in OVCAR-8 and OVCAR-3 was attributed
to the cells being subjected to chemotherapy prior to their removal from the patient,
whereas SHIN-3 and OVCAR-5 cells were extracted prior to administration of anticancer
agents.26, 29
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Figure 2.1. (A) Protein bands representative of NQO1 expression obtained from 2530 g protein using western blot for ovarian cancer cell monolayers, where SHIN-3,
OVCAR-5, OVCAR-8, and OVCAR-3 are respectively labeled as 1-4.
(B) Immunocytochemistry (immunofluorescence) performed on ovarian cancer cells
stained with anti-NQO1 mouse primary antibody and an AlexaFluor-488 mouse
secondary antibody. Images were obtained using 488-nm excitation and 490–515 nm
emission for NQO1 detection. Nuclear colocalization was achieved with DAPI stain.
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Because ICC/IF revealed NQO1 expressed in in OVCAR-8 and OVCAR-3 cells, but
bulk lysates assessed via western blot did not, RT-qPCR was conducted to determine
expression of NQO1 using a cDNA template derived from each cell line. Specifically, RTqPCR was used in presence/absence mode to evaluate the expression of the NQO1
gene. The qPCR data revealed that each ovarian cancer cell line studied indeed
expressed NQO1. Further examination of the Ct values, or the number of cycles to reach
a defined threshold, revealed that neither cell line displayed a statistically significant
difference in the number of cycles needed to amplify NQO1 and the -actin (Figure 2.2).
Moreover, in RT-qPCR the difference in Ct value (ΔCt) between the target gene, NQO1,
and the endogenous control, -actin, allows normalized gene expression of the target to
be evaluated. In practice, a more negative the Ct means increased expression of the
target gene. Taking this information into consideration, the Ct values obtained in this
study depicting the relative gene expression of NQO1 in each cell line are displayed in
Figure 2.2.
The relative gene expression of NQO1 between cell lines supported earlier findings
regarding NQO1 protein expression indicating a direct relationship between NQO1 gene
and protein levels in each cell line. It was determined that SHIN-3 and OVCAR-5 have
the highest relative gene expression of NQO1 followed by OVCAR-3, and OVCAR-8 has
the lowest. However, it was observed that the error bars representative of OVCAR-5 and
SHIN-3 overlapped, thus a t-test was performed to determine how insignificant the
difference in NQO1 gene expression was between the two cell lines and the calculated
p-value was 0.7.
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Figure 2.2. Relative gene expression of NQO1 (Ctmean) in OC cell monolayers. All
values represent gene expression normalized to -actin.

2.3.2 Spectrometric Determination NQO1 Activity
An

established

spectrometric

method

incorporating

a

quinone

substrate,

DCPIP, enabled the enzyme catalytic ability to be quantified over a 7-day period (Figure
2.3). It was found that NQO1 activity increased in each cell line over the 7-day period,
peaking around the fourth day of culture. However, OVCAR-5, OVCAR-8, and OVCAR-3
cells show a steady decline in activity starting at the fifth day of culture. NQO1 activity in
SHIN-3 cells appeared to have plateaued between days 4 and 6 before apparently
declining at day 7. The increased NQO1 activity observed between days 3 and 5 was
thought to be the result of the cells reaching 100% confluence, thus leading to them
consuming nutrients at a faster rate, which could result in hypoxia. Increased hypoxia
would lead to increased production of Hif- protein, which can then be used to initiate
both the production and enhanced activity of cytoprotective proteins, such as NQO1.30-31
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However, because the studied cells were grown in monolayers with a finite growth
area, rapid consumption of nutrients from culture media was believed to have resulted in
a NQO1 activity plateauing due to a possible increase in cell senescence. This conclusion
was supported by the rationale that senescence, or decline in proliferative ability, will likely
lead to metabolic processes (i.e., enzymatic activity) plateauing in to maintain
homeostasis.32-33 However, an analysis to determine exact phase of the cell cycle at
which confluent cell populations are in will have to be conducted to pinpoint whether
cellular senescence is taking place. Specifically, determining the expression of the bmi-1
gene, which regulates both senescence and proliferation would be advantageous. 32 An
alternative direction would be to determine the expression and activity levels of
senescence-associated biomarkers (e.g., -galactosidase) will have to be conducted to
determine if senescence is taking place once cell populations have become confluent.

34

Figure 2.3. NQO1 activity for ovarian cancer cell lines after 7 days of culture obtained
from enzymatic assay. 5 g/mL of protein was used for each sample.
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2.3.3 Visualization of NQO1 Activity via Fluorescent Probe Q3NTCy
Expression and activity were assessed to differentiate between the presence of active
NQO1 and inactive NQO1 due to both forms of the enzyme being detected by
immunochemical methods. Looking closely at the specific activity of NQO1 at day 4
(Figure 2.3), it was noted that the enzyme activity corroborated NQO1 presence in the
western blot and RT-qPCR data shown earlier. Therefore, the increased enzyme activity
observed in SHIN-3 and OVCAR-5 cells is strongly associated with of NQO1’s enhanced
expression in those cell lines relative to OVCAR-8 and OVCAR-3. Furthermore, the
moderate to low NQO1 activity observed in OVCAR-8 and OVCAR-3, was also found to
be correlated with lower expression of the enzyme. As a result, it was posited that upon
incubation with NQO1-activatable fluorescent probe Q3NTCy, an accurate visualization
of enzyme activity within cells could be achieved.
Q3NTCy is a fluorescent probe that can be used in either a turn-on or always-on
imaging mode due to a lack of overlap between the emission of the probe (em = 765-855
nm) and that of the reporter (em = 650-750 nm). Briefly, upon introduction of Q3NTCy to
NQO1-active cells, the quinone substrate (Q3) is selectively reduced and cleaved off, with
autonomous removal of the linker following, thereby resulting in the release of the highly
fluorescent TCy reporter.21, 24 Following fixation and subsequent staining of the nucleus,
cells are mounted onto glass slides and imaged using confocal microscopy. To visually
determine enzyme activity, the NQO1-activable probe Q3NTCy was introduced to cells
grown on coverslips 24 hours post culture. For comparative purposes, the NQO1-specific
activity measured one day after culture for bulk lysates of each cell line is shown in Figure
2.4. A. below (DCPIP reduction assay). Image analysis revealed there was significantly
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higher enzyme activity observed in OVCAR-5 and SHIN-3 cells, while little to no active
enzyme was found in OVCAR-8 and OVCAR-3 (Figure 2.4.

B).

The background

corrected mean fluorescence intensity was 22 2.8, 21 3.5, 5.4 0.7, and 2.3 0.4 for
SHIN-3, OVCAR-5, OVCAR-8, and OVCAR-3, respectively. These findings mimicked that
of the spectrometric analysis of cell lysates obtained after one day of culture. Thus,
validating my hypothesis that enzyme activity could be effectively measured using the
NQO1-activated fluorescent probe Q3NTCy.
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A.

B.

Figure 2.4. (A) NQO1 activity for ovarian cancer cell lines after 1 day of culture
obtained from enzymatic assay. 5 g/mL of protein was used for each sample. (B)
Ovarian cancer cells after treatment with 5 M Q3NTCy at 37 °C for 20 minutes.
Nuclear colocalization was achieved with DAPI nuclear stain.
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2.3.4 Proliferation of OC Cell Monolayers
Cellular proliferation was monitored in each cell line using an automated cell counter,
and the number of viable cells detected after growth in 2 mL of growth media (viable
cells/cm3) was recorded for each cell line every day for seven days (Figure 2.5). SHIN-3,
OVCAR-5, and OVCAR-8 all had doubling times, or the amount of time required for a
culture to reach twice the number cells, of less than 48 hours. On the other hand,
OVCAR-3 cells proliferated slowly with its doubling time being roughly 72 hours or more.
Earlier, it was noted that SHIN-3, OVCAR-5, and OVCAR-8 also had enhanced NQO1
activity when compared to OVCAR-3; thus, it was posited that proliferation may be
influenced by NQO1 activity. However, this assumption was challenged, due to
the proliferative ability of OVCAR-8 being similar to that of SHIN-3, with both surpassing
that of OVCAR-5. However, the NQO1 activity of SHIN-3 and OVCAR-5 was higher than
that of OVCAR-8. The apparent contradiction between these findings led to it being
concluded that NQO1 activity alone was not solely responsible for proliferation rates.

Figure 2.5. Monitoring proliferation of OVCAR cells over 7-days. The smooth curves
are merely provided as a guide to the eye for each cell line.
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2.4 Conclusions
In sum, NQO1 expression and activity in several ovarian cancer cell lines were
evaluated. Analysis of NQO1 expression prior to (i.e., RNA) and after (i.e., NQO1
enzyme) translation of the gene, revealed that SHIN-3 cells displayed the highest
expression and activity of NQO1, while OVCAR-3 was found to have the lowest
levels/values. Additionally, Q3NTCy activation by the enzyme shows that it is capable of
discriminating between cells derived from the same tissue as function of their respective
NQO1 activities. In addition, NQO1 activity was closely related to its expression in each
cell line, as evidenced by cells having more enzyme expressed having higher activity
levels, while those with lower expression having lower NQO1 activity. While a general
trend between NQO1 activity and the proliferation rates of SHIN-3, OVCAR-5, and
OVCAR-3 was observed, OVCAR-8 cells did not display the same trend. It is postulated
that the cancer stage, phenotype, and resistance to chemotherapy of OVCAR-8 may be
contributing to its enhanced proliferative abilities. Thus, one or more of these additional
factors could be influencing NQO1 activity in each cell line. The coming chapters will
further evaluate several of these factors.
2.5 References
1.
Konstantinopoulos, P. A.; Spentzos, D.; Fountzilas, E.; Francoeur, N.; Sanisetty,
S.; Grammatikos, A. P.; Hecht, J. L.; Cannistra, S. A., Keap1 mutations and Nrf2 pathway
activation in epithelial ovarian cancer. Cancer Research 2011.
2.
Singh, A.; Misra, V.; Thimmulappa, R. K.; Lee, H.; Ames, S.; Hoque, M. O.;
Herman, J. G.; Baylin, S. B.; Sidransky, D.; Gabrielson, E.; Brock, M. V.; Biswal, S.,
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer. PLOS Medicine
2006, 3 (10), e420.

66

3.
van der Wijst, M. G.; Huisman, C.; Mposhi, A.; Roelfes, G.; Rots, M. G., Targeting
Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion.
Molecular Oncology 2015, 9 (7), 1259-1273.
4.
Walker, A.; Singh, A.; Tully, E.; Woo, J.; Le, A.; Nguyen, T.; Biswal, S.; Sharma,
D.; Gabrielson, E., Nrf2 signaling and autophagy are complementary in protecting breast
cancer cells during glucose deprivation. Free Radical Biology and Medicine 2018, 120,
407-413.
5.
Cho, J.-M.; Manandhar, S.; Lee, H.-R.; Park, H.-M.; Kwak, M.-K., Role of the Nrf2antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer
cell resistance. Cancer Letters 2008, 260 (1-2), 96-108.
6.
Dinkova-Kostova, A. T.; Talalay, P., NAD (P) H: quinone acceptor oxidoreductase
1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector.
Archives of Biochemistry and Biophysics 2010, 501 (1), 116-123.
7.
Winski, S. L.; Koutalos, Y.; Bentley, D. L.; Ross, D., Subcellular Localization of
NAD(P)H:quinone Oxidoreductase 1 in Human Cancer Cells. Cancer Research 2002, 62
(5), 1420.
8.
Siegel, D.; Ross, D., Immunodetection of NAD (P) H: quinone oxidoreductase 1
(NQO1) in human tissues1. Free Radical Biology and Medicine 2000, 29 (3-4), 246-253.
9.
Cui, X.; Li, L.; Yan, G.; Meng, K.; Lin, Z.; Nan, Y.; Jin, G.; Li, C., High expression
of NQO1 is associated with poor prognosis in serous ovarian carcinoma. BMC Cancer
2015, 15 (1), 244.
10.
Lin, L.; Qin, Y.; Jin, T.; Liu, S.; Zhang, S.; Shen, X.; Lin, Z., Significance of NQO1
overexpression for prognostic evaluation of gastric adenocarcinoma. Experimental and
Molecular Pathology 2014, 96 (2), 200-205.
11.
Yang, Y.; Zhang, Y.; Wu, Q.; Cui, X.; Lin, Z.; Liu, S.; Chen, L., Clinical implications
of high NQO1 expression in breast cancers. Journal of Experimental & Clinical Cancer
Research 2014, 33 (1), 14.
12.
Lewis Anne, M.; Ough, M.; Hinkhouse Marilyn, M.; Tsao, M.-S.; Oberley Larry, W.;
Cullen Joseph, J., Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic
cancer. Molecular Carcinogenesis 2005, 43 (4), 215-224.

67

13.
Li, C. J.; Li, Y.-Z.; Pinto, A. V.; Pardee, A. B., Potent inhibition of tumor survival
&lt;em&gt;in vivo&lt;/em&gt; by β-lapachone plus taxol: Combining drugs imposes
different artificial checkpoints. Proceedings of the National Academy of Sciences 1999,
96 (23), 13369.
14.
Cabello, C. M.; Bair, W. B.; Bause, A. S.; Wondrak, G. T., Antimelanoma activity
of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1.
Biochemical Pharmacology 2009, 78 (4), 344-354.
15.
Siegel, D.; Yan, C.; Ross, D., NAD(P)H:quinone oxidoreductase 1 (NQO1) in the
sensitivity and resistance to antitumor quinones. Biochemical Pharmacology 2012, 83 (8),
1033-1040.
16.
Best, Q. A.; Johnson, A. E.; Prasai, B.; Rouillere, A.; McCarley, R. L.,
Environmentally robust rhodamine reporters for probe-based cellular detection of the
cancer-linked oxidoreductase hNQO1. ACS Chemical Biology 2015, 11 (1), 231-240.
17.
Best, Q. A.; Prasai, B.; Rouillere, A.; Johnson, A. E.; McCarley, R. L., Efficacious
fluorescence turn-on probe for high-contrast imaging of human cells overexpressing
quinone reductase activity. Chemical Communications 2017, 53 (4), 783-786.
18.
Hettiarachchi, S. U.; Prasai, B.; McCarley, R. L., Detection and Cellular Imaging of
Human Cancer Enzyme Using a Turn-On, Wavelength-Shiftable, Self-Immolative
Profluorophore. Journal of the American Chemical Society 2014, 136 (21), 7575-7578.
19.
Nawimanage, R. R.; Prasai, B.; Hettiarachchi, S. U.; McCarley, R. L., Rapid,
Photoinduced Electron Transfer-Modulated, Turn-on Fluorescent Probe for Detection and
Cellular Imaging of Biologically Significant Thiols. Analytical Chemistry 2014, 86 (24),
12266-12271.
20.
Prasai, B.; Silvers, W. C.; McCarley, R. L., Oxidoreductase-Facilitated
Visualization and Detection of Human Cancer Cells. Analytical Chemistry 2015, 87 (12),
6411-6418.
21.
Shen, Z.; Prasai, B.; Nakamura, Y.; Kobayashi, H.; Jackson, M. S.; McCarley, R.
L., A Near-Infrared, Wavelength-Shiftable, Turn-on Fluorescent Probe for the Detection
and Imaging of Cancer Tumor Cells. ACS Chemical Biology 2017, 12 (4), 1121-1132.
22.
Silvers, W. C.; Payne, A. S.; McCarley, R. L., Shedding light by cancer redox—
human NAD (P) H: quinone oxidoreductase 1 activation of a cloaked fluorescent dye.
Chemical Communications 2011, 47 (40), 11264-11266.
68

23.
Silvers, W. C.; Prasai, B.; Burk, D. H.; Brown, M. L.; McCarley, R. L.,
Profluorogenic Reductase Substrate for Rapid, Selective, and Sensitive Visualization and
Detection of Human Cancer Cells that Overexpress NQO1. Journal of the American
Chemical Society 2013, 135 (1), 309-314.
24.
Shen, Z., Visualization and Quantification of Cancer-associated Enzymes with
Fluorescent Small-molecule Substrate Probes. In LSU Doctoral Dissertations, Louisiana
State University: Baton Rouge, LA, 2018.
25.
Domcke, S.; Sinha, R.; Levine, D. A.; Sander, C.; Schultz, N., Evaluating cell lines
as tumour models by comparison of genomic profiles. Nature Communications 2013, 4,
2126.
26.
Imai, S.; Kiyozuka, Y.; Maeda, H.; Noda, T.; Hosick, H. L., Establishment and
Characterization of a Human Ovarian Serous Cystadenocarcinoma Cell Line That
Produces the Tumor Markers CA-125 and Tissue Polypeptide Antigen. Oncology 1990,
47 (2), 177-184.
27.
Hamilton, T. C.; Young, R. C.; McKoy, W. M.; Grotzinger, K. R.; Green, J. A.; Chu,
E. W.; Whang-Peng, J.; Rogan, A. M.; Green, W. R.; Ozols, R. F., Characterization of a
human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen
receptors. Cancer Research 1983, 43 (11), 5379-5389.
28.
Hsieh, T.-C.; Wu, J. M., Suppression of proliferation and oxidative stress by
extracts of Ganoderma lucidum in the ovarian cancer cell line OVCAR-3. International
Journal of Molecular Medicine 2011, 28 (6), 1065-1069.
29.
Hamilton, T. C.; Young, R. C.; Ozols, R. F. In Experimental model systems of
ovarian cancer: applications to the design and evaluation of new treatment approaches,
Seminars in Oncology, 1984; p 285.
30.
Kim, J.-w.; Tchernyshyov, I.; Semenza, G. L.; Dang, C. V., HIF-1-mediated
expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular
adaptation to hypoxia. Cell Metabolism 2006, 3 (3), 177-185.
31.
Sullivan, L. B.; Chandel, N. S., Mitochondrial reactive oxygen species and cancer.
Cancer & Metabolism 2014, 2 (1), 17.

69

32.
Jacobs, J. J.; Kieboom, K.; Marino, S.; DePinho, R. A.; van Lohuizen, M., The
oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence
through the ink4a locus. Nature 1999, 397 (6715), 164.
33.
Shay, J. W.; Wright, W. E., Senescence and immortalization: role of telomeres and
telomerase. Carcinogenesis 2005, 26 (5), 867-874.

34.
Debacq-Chainiaux, F.; Erusalimsky, J. D.; Campisi, J.; Toussaint, O., Protocols to
detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of
senescent cells in culture and in vivo. Nature Protocols 2009, 4 (12), 1798.

70

CHAPTER 3
EVALUATION OF TUMOR FORMATION FROM HUMAN OVARIAN
CANCER CELLS AS A FUNCTION OF NQO1 USING AN IN VITRO
SPHEROID MODEL
3.1 Introduction
While still a highly regarded form of in vitro cellular study, monolayer cultures do not
accurately reflect gene expression profiles that are found in clinical samples. 1 This is
primarily due to cells grown in monolayers lacking the functional and morphological
features of the tissues from which they were derived. In addition, monolayer cell cultures
are comprised of a homogeneous population of highly proliferative cells, with a flat,
stretched morphology. Therefore, studying cellular processes such as the cell cycle,
apoptosis, interactions with adjacent cells, and the extracellular matrix (ECM) in
monolayers is problematic, as monolayers do not exhibit the behavior and characteristics
of cells in vivo. The disadvantages of traditional two-dimensional, monolayer cell culture
are heightened when studying therapeutic response and efficacy.1-2 To overcome the
these drawbacks, the use of multicellular tumor spheroid mimics, otherwise known as
spheroids, has emerged as an alternative in vitro method to study cellular behaviors,
response to therapeutics, and most notably, cancer.1, 3
Spheroids are three-dimensional cellular structures that share physical attributes and
functionalities that closely resemble those of their parent tissues.4-6 Their structure results
in creation of metabolic and proliferative gradients that give rise to microregions of cells
with distinct gene expression profiles. These microregions, as depicted in Figure 3.1, are
composed of cells that are either proliferative, quiescent, hypoxic, or necrotic, with the
regions greatly impacted by their microenvironment.3, 6-7 The outermost region of cells, or
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the proliferative layer, has the highest exposure to nutrients and is in direct contact with
the ECM. The quiescent layer is composed of cells that have entered an inactive, or
resting state, because environmental conditions are not favorable for proliferation.
Quiescent cells are often viewed as the most problematic, because most anti-tumor drugs
target actively dividing cells; thus, this population of cells can go unscathed upon
chemotherapeutic agent exposure.8-9 Hypoxic conditions dominate the third microregion,
due to little to no oxygen or other needed nutrients for survival reaching the cells in this
layer. Research has shown that hypoxic cells, like those that are quiescent, are linked to
increased drug resistance, due to their ability to withstand harsh environmental
conditions.8, 10-11 The innermost layer is dubbed as necrotic, as it is composed of mostly
dead cells, due to little to no oxygen or other nutrients essential for growth being present.
Due to the differences in environment associated with each microregion, proteins
needed to promote not only continued proliferation, but also survival, are either
upregulated or downregulated. For example, several groups have found that NQO1
overexpression has been linked to poor prognosis in gastrointestinal, breast, prostate,
and pancreatic cancers.12-15 These findings have led the McCarley group to question the
role of NQO1 in tumor development, particularly in ovarian cancer. Cui and colleagues
have shown that NQO1 expression in serous ovarian carcinoma tissues is indicative of
poor prognosis.16 These findings were based on immunohistochemical staining of tissue
samples taken from patients with serous ovarian carcinoma, as well as borderline and
benign ovarian tumors. While previous reports have enhanced our overall understanding
of NQO1 expression in tumors, it has not been determined whether increased NQO1
expression in tumor tissues will result in increased enzymatic activity; that is, NQO1
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expression may not correlate with NQO1 activity levels. Moreover, the tumorigenic ability
of ovarian cancer cell lines has been evaluated in vivo and in vitro; however, the role of
NQO1 in tumor spheroid formation has yet to be determined.17-18

Proliferating
Quiescent
Hypoxic

Necrotic

Figure 3.1. Schematic of tumor microregions.

Based on literature regarding NQO1 overexpression in tumor tissues and the findings
presented in Chapter 2, it has been postulated that spheroid formation is more likely to
occur in those cell lines exhibiting high expression and activity of the enzyme in cell
monolayers.13-14, 16, 19 Therefore, to evaluate the influence of NQO1 on tumor growth and
development in ovarian cancer, I will employ an in vitro spheroid model. Specifically, I will
examine the propensity of the cell lines under investigation to form spheroids under
nonadherent conditions, due to such a transformation in cell growth/assembly capability
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being linked to metastatic disease. In addition, I will probe the influence of tumor
suppressor protein p53 on this process. Upon successful spheroid formation, I will then
examine NQO1 expression and activity levels using immunochemical techniques, in
addition to probe studies with the NQO1-activated Q3NTCy fluorescent probe.20
3.2 Experimental
3.2.1 Cell Culture
Human ovarian carcinoma cell lines OVCAR-5, OVCAR-8, and SHIN-3, gifts from Dr.
Hisataka Kobayashi at the United States National Institutes of Health, National Cancer
Institute, Center for Cancer Research, were used for the studies presented in this chapter.
Human ovarian carcinoma cell line OVCAR-3, purchased from American Type Culture
Collection (ATCC), was also used. Cells were cultured in RPMI-1640 medium purchased
from the ATCC that was supplemented with 10% fetal bovine serum (FBS; ATCC), 10
IU/mL penicillin and 10 g/mL streptomycin (Life Technologies). Bovine insulin (1 g/mL)
was an additional supplement for OVCAR-3 cells. Cells were cultured in 75 cm2 treated
tissue culture flasks at 37°C under 5% CO2 in a humidified incubator.
3.2.2 Multicellular Tumor Spheroid Culture
Spheroids were cultured in ultra-low attachment 96-well plates (Corning), as
previously described.7, 21 Briefly, cells were seeded at a density of 1 × 104 cells in each
well followed by the addition of growth medium supplemented with 10% FBS, 10 IU/mL
penicillin and 10 g/mL streptomycin. Medium was changed every 2 to 4 days, depending
on the cell line. In addition, to observe the ability of cells to form secondary and primary
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spheroids, primary spheroids were dissociated with 0.25% trypsin-EDTA solution,
counted, and cultured again under the same conditions as primary spheroids.
3.2.3 Stable NQO1 Protein Knockdown Assays
A custom shRNA clone set that targets all four reference sequence variants for NQO1
in psi-LVRU6GP composed of an U6 promoter, eGFP, and puromycin-resistant tags and
its respective shRNA scramble control clone was purchased from GeneCopoeia. Stable
knockdown of NQO1 was generated by infecting OVCAR-5 cells with polybrenesupplemented culture medium containing the lentiviral shRNA particles targeting NQO1
or the scramble control vector per the manufacturer’s instruction. Briefly, 48-hours after
culture, OVCAR-5 cells were transfected for 14–16 hours with polybrene-supplemented
(5 g/mL) medium containing either 10 g lentiviral shRNA particles or 10 g lentiviral
shRNA control particles. Medium was changed 16-hours post transfection, and cells were
cultured for an additional 48 hours before shRNA-NQO1 cells were isolated via puromycin
selection (2 g/mL).
3.2.4 Protein Quantification
To determine the total protein concentration, bulk protein was extracted from either
monolayers or from intact spheroids (n = 96). Following centrifugation at 900 rpm for 7
minutes at 4 °C to remove any excess cell media, 250-300 L of radioimmunoprecipitation
assay (RIPA, ThermoFisher) buffer with 1 mM phenylmethylsulfonyl fluoride (Sigma) and
protease inhibitor cocktail (Sigma) was added to monolayers and spheroids, and they
were placed on ice for 15 minutes and 30-45 minutes, respectively. Mechanical pipetting
was employed at 10-minute intervals to ensure homogeneity within the sample. Samples
75

were then centrifuged at 18,000 ×g for 20 minutes at 4 °C. The supernatant was obtained
and aliquoted into sterile Eppendorf tubes and stored at −80°C until used. Total protein
content was quantified using the well-established BCA assay.
3.2.5 Western Blot
NQO1 and p53 expression in the studied cell lines was measured in 25 μg protein
samples. Samples were measured using sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) using 4–20% polyacrylamide gels (Bio-Rad). 10 L of
Kaleidoscope Pre-Stained Standard marker was used to track proteins. Samples were
diluted in 2X Laemmli sample buffer containing 2-mercaptoethanol at a 1:1 ratio. Protein
separation was conducted at 100 V for 65 minutes in running buffer (Tris/Glycine/SDS),
followed by protein transfer onto nitrocellulose membranes in transfer buffer (Tris-Glycine
and 20% methanol). Following transfer, the membrane was blocked with 5% non-fat dry
milk for one hour before being washed with tris-buffered saline containing 0.1% Tween20 (TBST). Simultaneously, working concentrations of the primary mouse anti-NQO1 or
anti-p53 were prepared in 1% BSA in TBST. An anti--actin rabbit monoclonal antibody
was also introduced to the membranes as a loading control.
The membranes were kept overnight at 4 °C with gentle shaking on a microplate
shaker. After overnight incubation with the antibodies, the membrane was washed with
TBST 3X in 10-minute intervals. Next, both anti-mouse IgG and anti-rabbit IgG, HRPlinked secondary antibodies (Cell Signaling Technologies) were added to the membranes
for 1 hour at room temperature with gentle shaking. SuperSignal West Pico
chemiluminescent substrate was prepared based on the manufacturer’s protocol, and

76

slowly pipetted onto the membranes several times over a time period of roughly 2
minutes. Membranes were imaged using a Bio-Rad ChemiDoc MP system with an
exposure time of 300 seconds at 60 second intervals. Raw images were saved in tagged
image file format (TIFF), and band analysis was performed using Fiji/ImageJ software.
3.3.6 RNA Purification and Real-Time Quantitative PCR (RT-qPCR)
Total RNA from cell lines was extracted and purified for analysis using Direct-zol RNA
MicroPrep kit (Zymo Research) according to the manufacturer’s instructions. RNA was
quantified spectrometrically using an Epoch microplate reader (BioTek). Total RNA was
reversed transcribed to cDNA using TaqMan Reverse Transcriptase reaction mix
provided in the High Capacity RNA-to-cDNA Kit (Applied Biosystems) according to the
supplier’s instructions. The cDNA was diluted 1:10 in nuclease-free water and 2 L was
used as a template to perform RT-PCR in a 25 L reaction. -actin was used as an
endogenous control (Applied Biosystems, UK) in single-plexed PCR reactions on an ABI
ViiA-7 (qPCR) Detection System (Applied Biosystems) with fast thermocycling conditions
(50 °C for 2 minutes, 95 °C for 2 minutes, then 40 cycles at 95 °C for 1 second and 60 °C
for 20 seconds), using Taqman Fast Advanced PCR Master Mix (Applied Biosystems).
To confirm the modulated expression of the selected target gene and endogenous
control, TaqMan 20x gene expression primers and probes (Applied Biosystems) for TP53Hs01034249_m1 and ACTB-Hs99999903_m1 were used. All PCR reactions were
performed in triplicate.
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3.3.7 NQO1 Activity via Spectrometric Analysis/Enzyme Kinetics
NQO1 activity was assayed spectrometrically by the dicoumarol-sensitive reduction
of the quinone substrate 2,6-dichlorophenolindophenol (DCPIP) at 600 nm, as previously
described.22 The assay buffer consisted of 200 M NADH and 0.014% BSA in 25 mM of
Tris-HCl at pH 7.4 with or without 20 M dicoumarol, a known hNQO1 inhibitor. A fraction
of lysate was added to 0.75 mL of assay buffer to give a final protein concentration of 5

g in a 2 mL plastic cuvette. To start the reaction, 0.75 mL of 80 M DCPIP in assay
buffer was added, bringing the final volume to 1.5 mL. Enzymatic activity was determined
based on NQO1 ability to reduce the DCPIP substrate at 600 nm in the presence and
absence of the dicoumarol inhibitor. Each measurement was carried out using a Cary 50
UV/Vis spectrometer over a 2 to 10-minute timeframe, depending on the activity level of
cell line being assayed. Dicoumarol-sensitive NQO1 activity was then calculated by
subtracting the activity of a sample with dicoumarol from the corresponding activity
without dicoumarol. Finally, activity was recorded in units of nmol DCPIP reduced/mg/min.
3.2.8 Visualization of NQO1 Activity via Fluorescent Probe Q3NTCy
OVCAR cell monolayers were cultured overnight on 22 × 22 mm coverslips to allow
for attachment. Spheroids were cultured over a 5-day period in sterile ultralow attachment
plates (Corning) containing either RPMI-1640 or DMEM growth medium supplemented
with 10 % FBS and 10 IU/mL penicillin and 10 g/mL streptomycin. On the following day
(monolayers) and fifth day of culture (spheroids), cells were washed with PBS before
warmed RPMI-1640 medium (without phenol red) was added to each well. Q3NTCy probe
was added to each well to yield a final concentration of 5 M, which was then incubated
at 37 °C for 20 minutes for adherent cells and at intervals ranging from 30 minutes to 3
78

hours for spheroids. Following probe exposure, the culture medium was removed, and
cells or spheroids were washed with PBS 3X before 4% PFA was added. A 1-hour fixation
period with PFA was implemented in spheroids to ensure fixation occurred, after which
cells and spheroids were washed with PBS for an additional hour to ensure unreacted
probe was removed. Monolayer cells were then mounted on a glass slide using Prolong
Gold with DAPI (ThermoFisher), and subsequently cured overnight. Spheroids were
placed into delta T dishes containing RMPI-1640 media without FBS, and then imaged.
Confocal images were collected using a Leica TCS SP8 laser-scanning confocal
microscope. The TCy reporter that was released from the Q3NTCy probe upon exposure
to NQO1 was imaged using a white light laser. The TCy reporter was excited at 633 nm
with spectral emission was collected between 650–750 nm using hybrid detectors. The
pinhole was set at 1 Airy Unit (53.1 m). The DAPI nuclear stain was excited at 405 nm
by an argon laser with spectral emission collected between 410-483 nm. Each image was
frame and line averaged 4 and 2 times, respectively, at a scan speed of 8000 Hz. An Apo
plan 20X 0.3 NA objective was used. Image analysis was performed using LAS X and
Fiji/Image J software.
3.3 Results and Discussion
3.3.1 Anchorage-Independent Spheroid Formation in OC cells
Successful in vitro formation of spheroids without the use of support matrices, like
Matrigel or collagen, using ovarian cancer cells has been reported for HEY, OVCA429,
and ES-2 cells.23 OVCAR-3 cells were found to only have increased contractile behavior
upon the introduction of malignant ascites fluid to growth media; however, compact
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spheroid formation was not observed.24 Moreover, while the use of ascites fluid or
collagen may enhance cell line ability to contract, intrinsic factors play a major role in the
process. Thus, for my analysis, I studied the inherit ability of ovarian cancer cell lines to
form spheroids. SHIN-3, OVCAR-5, OVCAR-8, and OVCAR-3 cells were grown under
conditions that did not promote cell adhesion and were monitored over 5 days (Figure
3.2).
Sphere-forming capacity was evaluated using a modified version of a spheroid ranking
system based on the degree of compaction in ovarian cancer cells described by Sodek
and colleagues.23 In this modified scale, compact spheroids were defined as densely
packed spherical structures that remained intact upon mechanical pipetting. Semicompact spheroids were defined as densely packed structures that would partially
dissociate upon mechanical pipetting. Finally, spheroid aggregates were classified as
cells that readily aggregated, but were easily dissociated upon mechanical pipetting.
Applying this modified scale to my studies revealed that only OVCAR-8 cells were
capable of forming compact spheroids under the anchorage-independent conditions.
Moreover, while SHIN-3 cells produced spheroids, they were not as dense/compact as
were those of OVCAR-8. OVCAR-3 cells were used as a negative control, due to their in
vitro tumor-forming ability having been determined previously.23-24
In addition, upon mechanical agitation by pipetting, SHIN-3 spheroids began to break
apart; however, their complete dissociation was not observed. Unlike OVCAR-8 and
SHIN-3, OVCAR-5 produced aggregates that were easily dissociated upon mechanical
pipetting. The extent of spheroid formation in OVCAR-5 was intriguing, because of its
proliferative similarities to OVCAR-8 and SHIN-3 when cultured in monolayers. Aside
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from proliferative similarities, OVCAR-5 and SHIN-3 were found to exhibit increased
NQO1 expression and activity when compared to OVCAR-8 and OVCAR-3 cells, as
described in Chapter 2. Moreover, while the expression of NQO1 was similar in OVCAR8 and OVCAR-3, OVCAR-8 cells had higher enzyme activity. Based on these
observations, it was hypothesized that cells with exhibiting NQO1 activity greater than or
equal to that of OVCAR-8 have an increased propensity for spheroid formation.

A.

B.

C.

D.

Figure 3.2. Multicellular tumor spheroids after 5-days of culture. A. OVCAR-8,
B. SHIN-3, C. OVCAR-5, and D. OVCAR-3 cells were imaged using an inverted
microscope at 10X magnification. Image analysis was achieved using ImageJ/Fiji
software.

Sodek and colleagues observed compact spheroid formation with ovarian cancer cells
possessing an invasive, motile phenotype.23 Based on their work, I decided that it was
important to research the origin of the cell lines in this study, because the stage at which
cells were retrieved from patients will shed light on their level of invasiveness. OVCAR-8
cells were derived from a carboplatin refractory patient with advanced diseased, which is
perhaps why OVCAR-8 cells were able to form compact spheroids in an environment
lacking a support matrix.25-26 Unlike OVCAR-8, SHIN-3 cells were derived from a patient
with stage IIc disease, meaning the patient was close to, but had not yet acquired,
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metastatic disease.27 Therefore, it is likely that compact tumor formation in non-adherent
conditions would not occur due to the disease not reaching the level of invasiveness
observed in OVCAR-8. Further investigation into the origin of OVCAR-5 cells revealed
that like OVCAR-8, it was obtained from a tumor from a patient with advance disease. 18
However, it should be noted that both OVCAR-5 and SHIN-3 cells were retrieved from
patients who had not yet been treated. Moreover, while OVCAR-3 cells were derived from
a cisplatin-resistant patient, they were retrieved from malignant ascites; this is in contrast
to the other cell lines in this study, because they were derived from solid tumors. This
distinction may be related to the observation that OVCAR-3 cells did not form spheroids
or aggregates (Figure 3.2. D.), while also pinpointing to the rationale for increased
compaction and aggregation being observed in OVCAR-8, SHIN-3, and OVCAR-5 cells.
3.3.2 Manipulation of NQO1 gene expression in OVCAR-5 cells
In the previous section, it was observed cell lines displaying NQO1 activity greater
than or equal to that of OVCAR-8 had increased ability to form spheroids/aggregates
(Figure 3.2.). Therefore, it was hypothesized that NQO1 is necessary for
spheroid/aggregate formation under anchorage-independent conditions. To test this new
hypothesis, I performed gene expression experiments aimed at depleting NQO1 in
OVCAR-5 cells. OVCAR-5 cells were chosen for this study because their origin, in regard
to the cancer stage at which it was retrieved, and proliferative ability was similar to that of
OVCAR-8. To ensure stable knockdown of the NQO1 gene, lentiviral particles against
NQO1 expressing a puromycin-resistant gene was introduced to OVCAR-5 cells. After
transfection of OVCAR-5 cells with lentiviral particles, puromycin, an antibiotic that will
selectively eliminate cells that do not express the puromycin-resistant gene, was added
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and NQO1-depleted cells were isolated. I performed western blotting, enzyme kinetics,
and treatment of the cells with NQO1-activated probe Q3NTCy to further validate that the
transfection was a success.
As shown in Figure 3.3. A., NQO1 expression was diminished in OVCAR-5 with
depleted NQO1 (NQO1(-)) when compared to OVCAR-5 wildtype (WT) cells. The
catalytic ability of NQO1(-) after 4-days of culture (Figure 3.3 B) was determined to be
21.4 nmol/min/mg; thus, the enzyme’s activity was observed to be 7 times lower than
when compared to WT cells cultured under the same conditions. Incubation with Q3NTCy
allowed NQO1 activity to be evaluated visually. Image analysis revealed that the
fluorescence intensity resulting from NQO1-activated release of the TCy reporter was
considerably higher in OVCAR-5 WT cells with a mean integrated fluorescence intensity
of 14 ± 6 compared to 2.0 ± 0.4 in NQO1(-) OVCAR-5 cells (Figure 3.3. C). Here again,
the NQO1-depleted OVCAR-5 cells exhibited 7 times lower NQO1 activity in comparison
to that of the wildtype OVCAR-5 cells.
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WT

NQO1 (-)

NQO1
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C.

Figure 3.3. (A) Protein bands representative of NQO1 expression using 25 g of
protein extracted from wildtype and NQO1(-) OVCAR-5 cells. -actin was used as an
internal standard. (B) NQO1 activity for ovarian cancer cell lines after 1-day of culture
obtained from enzymatic assay. 2.5 g/mL and 5 g/mL protein used in WT and
NQO1(-) OVCAR-5 cells, respectively. (*** denotes a p-value <0.001). (C) OVCAR-5
wildtype and NQO1(-) cells after treatment with 5 M Q3NTCy at 37°C for 20 minutes.
Nuclear colocalization was achieved with a DAPI nuclear stain.
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The newly created NQO1-negative OVCAR-5 cells were then plated under
anchorage-independent conditions for 5-days to determine if spheroid formation would
occur. At day 5, the spheroids were imaged with an inverted microscope (Figure 3.4.).
Neither aggregation nor compact spheroid formation was observed in the OVCAR-5 cells
depleted of NQO1. The lack of spheroid formation confirmed my hypothesis was correct
regarding NQO1 expression/activity being necessary for successful spheroid and/or
aggregate formation. In fact, these findings are similar in many ways to those observed
by Madajewski in non-small cell lung cancer cells, which were found to have diminished
colony forming potential upon NQO1 depletion.28 Based on these findings, it was posited
that highly invasive ovarian cancer cells with moderate to high expression of NQO1 may
be necessary to observe spheroid and/or aggregate formation in vitro.

A.

B.

Figure 3.4. OVCAR-5 (A) WT and (B) NQO1 (-) cells after 5-days of culture in nonadherent conditions. Images were obtained with an Olympus IX81 brightfield
fluorescence microscope at 10X magnification.
3.3.3 Expression of p53 in OC cells
While the ability of the studied cell lines to produce spheroids as a function of NQO1
was intriguing, it added a layer of depth to this research. Literature studies indicate that

85

tumor suppressor protein p53 is stabilized by NQO1; thus, increased NQO1 presence
and/or activeness should make tumor formation less likely.29-30 Based on my findings, this
rationale holds true to some extent, due to OVCAR-8 cells, which exhibited low activity
and undetectable expression of NQO1 in bulk samples, being capable of compact
spheroid formation. However, the appearance of spheroids/aggregates in the SHIN-3 and
OVCAR-5 WT cells, both of which displayed high expression and activity of NQO1,
contradicts the notion that increased presence and/or activeness of the enzyme will
negatively impact tumor formation. Furthermore, evaluation of OVCAR-5 NQO1 (-) cells
revealed that they were unable to form spheroids/aggregates, which should have resulted
in spheroid/aggregate formation due to p53 being unstable.
To explore these findings, western blot analysis was used to probe p53 expression in
OVCAR-5, OVCAR-8, SHIN-3, and OVCAR-3. Figure 3.5 depicts the results of western
blot analysis of bulk protein extracted from ovarian cancer cell monolayers. Dense bands
corresponding to p53 protein expression were observed for OVCAR-8 and SHIN-3 cells.
It was concluded that the enhanced p53 protein expression in OVCAR-8 may have been
due to the cells attempting to inhibit tumor formation. However, one of NQO1’s functions
is to stabilize p53 so that it does not undergo proteasomal degradation, and OVCAR-8
has low NQO1 expression, so it was surprising that p53 expression was so pronounced. 3031

Similarly, SHIN-3 was found to express p53 protein, but because of its high expression

and activity of NQO1, it was proposed that semi-compact spheroid formation was likely
the result of partial tumor suppression by p53. Unlike OVCAR-8 and SHIN-3, p53 protein
expression was low and undetectable in OVCAR-3 and OVCAR-5, respectively.
Theoretically low and/or no expression of p53 gene and/or protein should result in
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increased tumor-forming ability, which to an extent holds true for OVCAR-5 WT cells, as
aggregation with them was observed, but neither spheroid formation nor aggregation was
observed in OVCAR-3 cells.
To determine whether the expression of p53 in protein form was indicative of its
expression at the genomic level, the relative gene expression of p53 in each cell line is
shown in Figure 3.5. B. Surprisingly, OVCAR-3 cells had the highest relative gene
expression of p53 followed by SHIN-3 andOVCAR-8 cells, while gene expression in
OVCAR-5 cells was lowest. Also, the difference in p53 gene expression between
OVCAR-8 and SHIN-3 was statistically insignificant (p = 0.07). However, the most
profound observation of this study was that it contradicted the western blot results shown
in Figure 3.5. A. Specifically, OVCAR-3 was found to highest expression of the p53 gene,
but its expression of the translated protein form was noticeably lower than that of OVCAR8 and SHIN-3. Similarly, both SHIN-3 and OVCAR-8 displayed enhanced expression of
the p53 protein, while the gene expression was low relative to OVCAR-3. Also, although
OVCAR-5 cells did not appear to express the p53 protein, the gene was present, though
it was expressed at a much lower degree compared to the other cell lines.
Moreover, the findings presented in this section suggest that modifications in either
the p53 gene sequence or the translated protein may have occurred in the studied cell
lines. Literature suggests that the expression of a gene is not always reflective of the
presence of the translated protein.32-34 In addition, it has been found that posttranslational
accumulation of p53 may inhibit its proteasomal degradation. 35 Previous research has
reported mutations in the p53 gene in 73% of ovarian cancer cells. 36 Moreover, it was
found that the p53 gene in OVCAR-8 and OVCAR-3 cells has mutations within its
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nucleotide sequence resulting from guanine being replaced by adenine within their DNA
sequences.36-37 Such mutations may be responsible for spheroid formation or lack thereof
in OVCAR-8 and OVCAR-3 cells, respectively. To my knowledge, p53 expression in
SHIN-3 cells has not been evaluated prior to my studies; therefore, mutations, if any, in
the gene sequence of p53 have not been identified. Additionally, the status of p53 in
OVCAR-5 cells has led to conflicting narratives of regarding its expression. While the
catalogue of somatic mutations in cancer (COSMIC) identified wildtype p53 in OVCAR-5
cells, other researchers have found that the cell line is p53 null. 36-39 However, it was
unclear whether the latter were based their findings on the expression of the p53 gene or
protein. Based on my findings, it was posited that low expression of the p53 gene in
OVCAR-5 WT cells results in little to no p53 protein being expressed.
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Figure 3.5. (A) Protein bands representative of p53 expression in 25 g samples of
(A) OVCAR-5 WT, (B) OVCAR-8, (C) SHIN-3, and (D) OVCAR-3. -actin was used as
an internal standard. (B) Relative gene expression of p53 (Ctmean) in OC cell
monolayers.
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3.3.4 NQO1 Expression and Activity in OVCAR-8 and SHIN-3 Spheroids
At the beginning of this chapter, it was stated that there are observable differences
in gene expression between monolayer and spheroid models of disease. Thus, to
evaluate whether differences in the expression and activity of NQO1 was altered in
spheroids, OVCAR-8 and SHIN-3 cells were grown under anchorage-independent
conditions and harvested on the 5th and 12th days of culture. NQO1 expression level was
found to be invariant in OVCAR-8 and SHIN-3 spheroids regardless of culture time.
Interestingly, NQO1 presence was detectable in OVCAR-8 spheroids via western blot
(Figure 3.6.), but not in OVCAR-8 cells grown in traditional monolayer culture (Chapter 2,
Figure 2.2 A). Moreover, the expression of NQO1 in SHIN-3 spheroids was found to be
increased, as the band density corresponding to the enzyme in spheroids is much higher
than that for monolayers. This outcome is attributed to less oxygen and nutrients reaching
cells housed in the innermost microregions of spheroids, thereby yielding increased
expression of cytoprotective proteins, such as NQO1. In addition, these findings support
studies
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samples.13-14, 16, 19, 40
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NQO1
β-actin
Figure 3.6. Protein bands representing levels of NQO1 activity in 5-day-old (1)
OVCAR-8 and (3) SHIN-3, and 12-day old (2) OVCAR-8 and (4) SHIN-3 spheroids,
using 25 µg of protein. β-actin was used as an internal standard.
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Upon examining whether enhanced expression of the enzyme yields increased activity
in OVCAR-8 spheroids, it was determined that NQO1 activity was comparable to that of
OVCAR-8 monolayers after 1-2 days of culture. Therefore, it was surmised that culture
time did not greatly impact NQO1 activity levels in spheroids. This finding was supported
when two-tailed statistical analysis led to the conclusion that there is no significant
difference in NQO1 activity for 5-day-old and 12-day old OVCAR-8 spheroids (p = 0.11).
Similarly, SHIN-3 spheroids exhibited lower NQO1 activity than SHIN-3 cell monolayers
of the same growth age. Specifically, 5-day old SHIN-3 monolayers had an NQO1 activity
value of 1193 ± 42 nmol/min/mg, while 5-day old spheroids had one of 82 ± 2
nmol/min/mg. Despite the observed decrease in NQO1 activity in SHIN-3 spheroids
relative to monolayers, there was a statistical difference (p = 0.02) in NQO1 activity
between day-5 and day-12 SHIN-3 spheroids. Thus, suggesting that NQO1 activity
increases with time in SHIN-3 spheroids. Also, no statistical difference in NQO1 activity
(p = 0.33 and p = 0.69) was found when comparing 5-day-old and 12-day-old OVCAR-8
and SHIN-3 spheroids, respectively. Therefore, these findings are in contrast to those
observed in cell monolayers, where it was determined that a difference in activity existed
between the two cell lines. In addition, these findings further support the notion that gene
expression and the behavior of cells in monolayer culture is not entirely reflective of how
those same cells will behave in three-dimensional culture.
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Figure 3.7. Specific activity of NQO1 from bulk protein lysates collected from
OVCAR-8 and SHIN-3 spheroids where the asterisk denotes a statistical difference
in activity (p < 0.05) within a 95% confidence interval.

These findings, specifically, the differences in NQO1 expression and activity between
2-dimensional and 3-dimensional culture, support literature on behavior of cells in
monolayers not accurately depicting how cells will behave in tissues. Therefore, in
analyzing the data based solely on my findings in spheroid culture, it was posited that
lower NQO1 activity could be due to the different nutrient gradients in spheroids, leading
to more active enzyme being present in the layer of cells in direct contact with nutrients
and oxygen. Moreover, cells that are in a state of quiescence or hypoxia in the inner layers
of the spheroids, which are considered to be in a state of rest, have the potential to
contribute to NQO1 activity if environmental conditions change. For instance, if a patient
is treated with radiation therapy, which targets actively dividing cells, it will likely only have
an effect on the outer proliferating layer of cells within a tumor. Thus, cells present within
the quiescent level are left unharmed. Due to their newfound exposure to the ECM and
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its nutrients, quiescent cells within a tumor can begin actively dividing again, which could
lead to increased activity in cytoprotective proteins, like NQO1.
3.3.5 Visualization of NQO1 Activity in OVCAR-8 and SHIN-3 Spheroids via Q3NTCy
To determine the applicability of NQO1-activated fluorescent probe Q3NTCy in threedimensional models of cancer, it was introduced to OVCAR-8 and SHIN-3 spheroids a
concentration of 5 M (Figures 3.8. and 3.9.). Probe activation was evaluated by varying
the probe incubation time—30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, and 3 hours.
Following three successive 20-minute washes and a 1-hour fixation period, samples were
imaged with confocal fluorescence microscopy. Confocal microscopy was useful for
obtaining high-resolution images of spheroids using Q3NTCy in an OFF-ON mode, which
would only allow for fluorescence light emitted from the TCy reporter to be detected. At
first glance, it can be assumed that NQO1 activity is higher at the periphery of the
OVCAR-8 and SHIN-3 spheroids. This suggests that probe penetration through the
spheroids is occurring, but little to no active NQO1 is present in the inner levels of
spheroids. However, previously published findings with Q3STCy probe in spheroids
derived from colorectal cancer cell line, HT-29, contradict this notion.41 Specifically, it
was found that increased NQO1 activity was localized that the periphery of aged
spheroids whose necrotic region was enlarged.41 Considering the age of the spheroids
from previous studies (i.e., 23 days old) and those presented in this study (5 days old), it
is plausible that active NQO1 distributed throughout younger spheroids. This assumption
is supported by unpublished findings in the McCarley lab in live 5-day-old HT-29
spheroids. In this study, spheroids were sectioned (i.e., sliced) and exposed to Q3NTCy
for 10-minutes and upon imaging, an even fluorescence signal was observed across the
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spheroid.20 Thus, it was concluded that not only was active enzyme was present in the
interior of spheroids, but limited penetration of light through intact spheroids rendered it
impossible to detect emitted light beyond 100 µm.

Figure 3.8. 5-day-old OVCAR-8 spheroids after incubation at 37 °C and 5% CO2 with
5 M Q3NTCy in RPMI-1640 without phenol red for A.) 30 minutes, B.) 1 hour, C.) 2
hours, D.) 2.5 hours, E.) 3 hours. Images were acquired using confocal fluorescence
microscopy using 20X magnification. Differential interference contrast (DIC) images
were taken at each time point.

Figure 3.9. 5-day-old SHIN-3 aggregates after incubation at 37 °C and 5% CO2 with 5
M Q3NTCy without phenol red for A.) 30 minutes, B.) 1 hour, C.) 2 hours, D.) 2.5
hours, E.) 3 hours. Images were acquired using confocal fluorescence microscopy
using 20X magnification. Differential interference contrast (DIC) images were taken at
each time point.
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3.4 Conclusion
In summary, the tumorigenic potential of several ovarian cancer cell lines was
evaluated under anchorage-independent conditions. Initially, it was hypothesized that
spheroid formation is correlated with increased expression and activity of NQO1. It was
found that three of the four cell lines formed spheroid and/or aggregates. One of which
was OVCAR-8, whose NQO1 expression and activity was low, thus rejecting my initial
hypothesis. In addition, by employing the modified scale to define spheroid/aggregates it
was observed that OVCAR-8, SHIN-3, and OVCAR-5 WT cells produced a compact
spheroid, semi-compact spheroids, and loose aggregates, respectively. Due to OVCAR8’s spheroid forming ability and its associated low expression/activity of NQO1, I opted to
perform a NQO1 knockdown in OVCAR-5 cells to determine whether depleting NQO1
would still result in the formation of an aggregate. Interestingly, depleting NQO1 in
OVCAR-5 cells had the opposite effect, with aggregation being inhibited. Therefore, I
concluded that NQO1 expression and activity that was greater than or equal to that
observed in OVCAR-8 cells was necessary to induce spheroid/aggregate formation.
However, I decided to examine the expression of tumor suppressor gene p53, which
is stabilized by NQO1.30 It was found that an indirect relationship between p53 gene and
protein expression was observed in three of the four cell lines presented in this study.
While OVCAR-3 cells highly expressed the p53 gene, they exhibited low expression of
the p53 protein. On the contrary, SHIN-3 and OVCAR-8 highly expressed the p53 protein,
while their p53 gene expression was low compared to that observed in OVCAR-3. Unlike
the other cell lines in this study, p53 gene and protein expression in OVCAR-5 WT cells
were directly related (i.e., low and undetectable expression of the gene and protein,
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respectively). Expanding these new findings to include those of the spheroid formation
studies, it was determined that cell lines with enhanced expression of the p53 protein
formed compact or semi-compact spheroids (i.e., OVCAR-8 and SHIN-3, respectively),
while OVCAR-5 cells, whose p53 gene and protein expression levels were low, were
capable of aggregate formation. Moreover, OVCAR-3 cells with high p53 gene and low
p53 protein expression compared to OVCAR-8 and SHIN-3 cells, were not capable of
spheroid or aggregate formation. Therefore, it was concluded that p53 protein expression
greater than or equal to that of OVCAR-5 was likely to be involved in spheroid and/or
aggregate formation in the studied cell lines. Furthermore, these findings support the
observation that cell lines exhibiting NQO1 activity greater than or equal to that of
OVCAR-8 are more likely to form spheroids or aggregates under the anchorageindependent conditions. Despite this, further assessment of additional factors that may
be aiding in this process will be detailed in the next chapter.
Aside from probing the role of NQO1 in spheroid formation, I also worked to determine
the level of expression and activity of enzyme in the cell lines that displayed enhanced
ability to form compact spheroids. NQO1’s presence was found upregulated in OVCAR8 spheroids when compared to monolayer culture, whereas its expression was constant
in 2-dimensional and 3-dimensional culture of SHIN-3. However, enzyme activity in
spheroids of either cell line was found to be comparable to that in monolayer culture of
OVCAR-8 after 2 days. Despite the decrease in activity of spheroids when compared to
monolayers cultured for the same amount of time, the NQO1-activated probe Q3NTCy
was activated by the enzyme in as little as 30 minutes with an increase in reporter release
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after prolonged exposure (≥1-hour). However, due to the lack of light penetration through
spheroids, the applicability of Q3NTCy for imaging of thick tissue samples is limited.
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CHAPTER 4
DETERMINATION OF CANCER STEM CELL PRESENCE AND
PHENOTYPIC HETEROGENEITY IN 2-DIMENSIONAL AND 3DIMENSIONAL MODELS OF OVARIAN CANCER

4.1 Introduction
Oncogenic transformation is speculated to be the result of a small subset of cancer
cells that have acquired stem-like functions.1-2 These cells, dubbed cancer stem cells
(CSC), have the ability to self-renew and produce daughter cells capable of shifting into
phenotypes that often cross lineages.2-3 The stem-like nature of these cells enables them
to adapt to environmental changes, such as a diminished nutrient supply and exposure
to chemotherapeutics, thus leading to increased survival.4 Due to its 70% recurrence rate
after initial treatment, CSC presence in ovarian cancer has been of great interest to
researchers.5-6 As detailed in Chapter 1 ovarian cancer-associated CSC markers have
been identified as having increased tumor-initiating ability, invasiveness, angiogenic
ability, and chemoresistance in vivo.6 Several biomarkers have been found to be
associated with ovarian CSCs, four of which will be highlighted in the following section. 6
CD133, or Prominin-1, is one of the most widely studied ovarian CSC markers to date.
Several researchers have shown that CD133-positive cells from both established and
primary ovarian cells have increased tumor-initiating capacity.7-8 Curley and colleagues
isolated a CD133-negative population of cells that gave rise to a tumor composed of 10%
CD133-positive cells in immunocompromised mice.7 These findings suggest that either
CD133-negative cells transform into CD133-postive ones, or as little as 1% CD133positive cells have the ability to drive tumor formation.7 Aside from these findings, Kryczek
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and colleagues observed that both in vitro and in vivo spheroid forming ability was
increased in cells that co-expressed aldehyde dehydrogenase isozyme-1 (ALDHA1) and
CD133.9 Similarly, Silva et al. observed that co-expression of CD133 and ALDHA1
resulted in increased tumorigenic and angiogenic potential in immunocompromised
mice.10 Additionally, they found that ALDHA1-positive cells isolated from CD133-negative
primary and established cell lines could give rise to tumors in mice, while ALDHA1negative cells could not. This suggests that ALDHA1 expression, like CD133, is correlated
with increased tumorigenic potential.

It was noted that primary tumor cells and

established cell lines have different propensities for tumor formation in vivo related to the
expression of CD133 and ALDHA1. Specifically, established cell lines positive for CD133
but lacking ALDHA1 could form tumors in mice, while primary tumor cells could not. 10
Aside from CD133 and ALDHA1, hyaluronic acid receptor CD44, has been implicated
as a CSC marker in breast, prostate, colorectal, and pancreatic cancer, due to
populations enriched for it being highly tumorigenic.11-14 Its expression has been
associated with enhanced cell adhesion and binding to extracellular matrix proteins that
are highly expressed in solid tumors.15-16 Alvero and colleagues found that patients with
metastatic disease had enhanced CD44 expression.17 In the same study, isolated primary
cells showed increased frequency of tumor formation and resembled the native tissue
when harvested in mice. In a follow-up study, it was found that CD44-positive cells were
capable of differentiating into human CD34-expressing blood vessels, thus indicating that
they are involved in angiogenesis.6, 18 Like CD133 and CD44, CD117 is a surface protein
whose function is to maintain cells in an undifferentiated state and promote self-renewal
in embryonic, hematopoietic, and mesenchymal stem cells, and has also been identified
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as an ovarian CSC.19-21 Lu et al. observed that populations of CD117-positive cells were
capable of asymmetric division, tumorigenesis, and increased chemo-resistance.22 In a
different study, Zhang and colleagues identified a population of cells co-expressing CD44
and CD117, which were observed to be tumorigenic and chemoresistant in vivo. 6, 23
Apart from CSC presence, phenotypic heterogeneity within tumors has been linked to
increased metastasis, chemoresistance, and recurrence. Cancer cells have been shown
to undergo phenotypic transitions in an effort to not only aid their spread to distant tissues,
but also in response to environmental stressors. Such changes in phenotype, as detailed
in Chapter 1, are the result of an epithelial-to-mesenchymal transition, or EMT. It is
speculated that during neoplastic progression, ovarian cancer tumors are composed of
cells having an epithelial phenotype, but as the disease advances, they acquire
mesenchymal features, thus resulting in metastatic disease.

24

However, there are

populations of cells that may exhibit features of one or both phenotypes. In one study, it
was found that a side population of ovarian cancer cells, derived from primary ascites and
mesenchymal cells, were epithelial; whereas the remaining cells were found to be
mesenchymal.25 In a separate study, Strauss et al. isolated populations of ovarian cancer
cells from mouse xenografts and tissue culture that expressed a hybrid epithelialmesenchymal phenotype.26 While the two previously mentioned works were
representative of cells derived from patient samples, Gardi and colleagues found that
established ovarian cancer cell lines underwent phenotypic transitions when cultured in
vitro under conditions that either promoted or inhibited attachment to an extracellular
matrix (ECM) substrate.27 Each study indicates that phenotypic heterogeneity is not
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limited to cells cultured in vivo, thus suggesting that monitoring these changes in vitro will
also not compromise the integrity of information.
In Chapter 3, it was determined that NQO1 could not be implicated as the sole driving
force behind spheroid formation, though NQO1 activity in cells and their ability to form
spheroids and/or aggregates appeared to be related. These findings mirrored those
presented in Chapter 2, where it was observed that NQO1 activity and proliferative ability
were connected in three of the four studied cell lines. To pinpoint additional factors that
may have an impact on proliferation and tumorigenesis in ovarian cancer, CSC presence
and the phenotypic nature of each cell line in two-dimensional and three-dimensional
culture will be evaluated. Furthermore, similarities and differences that exist between
CSC expression and cell phenotype in two-dimensional and three-dimensional culture will
be examined.
4.2 Experimental
4.2.1 Cell Culture
Human ovarian carcinoma cell lines SHIN-3, OVCAR-5, and OVCAR-8 were gifts from
Dr. Hisataka Kobayashi at the United States National Institutes of Health, National Cancer
Institute, Center for Cancer Research. Human ovarian carcinoma cell line OVCAR-3 was
purchased from American Type Culture Collection (ATCC). All cell lines were cultured in
either DMEM or RPMI-1640 medium purchased from ATCC supplemented with 10% fetal
bovine serum (FBS; ATCC), 10 IU/mL penicillin and 10 g/mL streptomycin (Life
Technologies) unless stated otherwise. Bovine insulin (1 g/mL) was an additional
supplement for OVCAR-3 cells. Cells were cultured in 75 cm2 treated tissue culture flasks
at 37 °C under 5% CO2 in a humidified incubator.
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4.2.2 Multicellular Tumor Spheroid Culture
MCTS were cultured in ultra-low attachment dishes (Corning). Briefly, cells were
seeded at 1 × 104 cells in each well of a 96-well plate coated with 1% agarose. Medium
was changed every 2 to 4 days, depending on the cell line.
4.2.3 Protein Quantification
Protein quantification was carried out as described in Chapters 2 and 3. Briefly,
monolayer cells were dissociated from culture dishes using trypsin-EDTA, while intact
spheroids were harvested from 96-well plates. Monolayer cells were centrifuged at 900
rpm for 7 minutes at 4 °C, to remove tryspin-EDTA or media, followed by the introduction
of 150-200 L of radioimmunoprecipitation assay (RIPA, ThermoFisher) buffer with 1 mM
phenylmethylsulfonyl fluoride (Sigma) and protease inhibitor cocktail (Sigma). Intact
spheroids (n=96) were exposed to 250 L of RIPA buffer with 1 mM phenylmethylsulfonyl
fluoride (Sigma) and protease inhibitor cocktail (Sigma) for 30–45 minutes on ice.
Mechanical pipetting was employed at 10-minute intervals to ensure that all cells with
each sample were lysed. Monolayer and spheroid samples were then centrifuged at
18,000 ×g for 20 minutes at 4 °C. The supernatant was obtained and aliquoted into sterile
Eppendorf tubes at −80 °C until use. Total protein content was quantified using a wellestablished BCA assay.
4.2.4 Western Blot
CSC and EMT marker expression were measured in 25 g protein samples. Samples
were measured using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDSPAGE) using 4–20% polyacrylamide gels (Bio-Rad). 10 L of Kaleidoscope Pre-Stained
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Standard marker was used to track proteins. Samples were diluted in 2X Laemmli sample
buffer containing 2-mercaptoethanol at a 1:1 ratio. Protein separation was conducted at
100 V for 65 minutes in running buffer (Tris/Glycine/SDS), followed by protein transfer
onto nitrocellulose membranes in transfer buffer (Tris-Glycine and 20% methanol).
Following transfer, the membrane was blocked with 5% non-fat dry milk (NFDM) for one
hour before being washed with TBST solution.
To assess stemness, mouse anti-CD44, rabbit anti-CD133, and rabbit anti-ALDHA1
(Cell Signaling Technologies) and a mouse anti-CD117 antibody (Santa Cruz) were used.
EMT was evaluated with primary monoclonal antibodies rabbit anti-vimentin, rabbit antiE-cadherin, rabbit anti-N-Cadherin, and mouse anti-EpCAM antibodies, all of which were
purchased from Cell Signaling Technologies. An anti--actin monoclonal antibody (Cell
Signaling Technologies) was also introduced to the membranes as a loading control. All
antibodies were diluted to a 1:1000 concentration in NFDM. The membranes were kept
overnight at 4 °C with gentle shaking. After overnight incubation with the antibodies,
membranes were washed with TBST 3X in 10-minute intervals. The following day, both
mouse anti-IgG and rabbit anti-IgG, HRP-linked secondary antibodies (Cell Signaling
Technologies) were added to the membranes for 1 hour at room temperature with gentle
shaking. Super Signal West Pico chemiluminescent substrate was prepared based on the
manufacturer’s protocol, and slowly pipetted onto the membranes several times for
roughly two minutes. Membranes were imaged using a Bio-Rad ChemiDoc MP system
with an exposure time of 300 seconds at 60 second intervals. Raw images were saved
as tagged image file format (TIFF) files, and band analysis was performed using
Fiji/ImageJ software.
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4.2.5 Immunocytochemistry/Immunofluorescence (ICC/IF)
OVCAR-5, SHIN-3, OVCAR-8, and OVCAR-3 cells were cultured overnight in a 16well chambered slide (LabTek) at 37 °C. The following day, cells were washed with ice
cold PBS for 5 minutes to remove excess media. Samples were then treated with 200 L
of cold 4% paraformaldehyde (PFA) for 20 minutes in the dark at room temperature. Once
the fixation step was completed, samples were washed with ice-cold PBS for 5 minutes.
Samples were then permeabilized with 3% Tween-20 in PBS (PBST) for 15 minutes at
37 °C. 200 L 5% BSA in PBST (PBS with 1% Tween-20) was added to the cells for 1hour to allow for blocking. While the cells were blocked, a working concentration of each
primary antibody vimentin, N-cadherin, E-cadherin, EpCAM, CD44, CD133, ALDHA1 and
CD117 was prepared in 1% BSA in PBST at 1:200 dilutions. The antibody solutions were
added at the volume of 200 μL per well. The slides were then incubated at 4 °C for 1 hour
with shaking. Following removal of the primary antibody solutions, samples were washed
with PBST 3X for 10 minutes. Goat anti-mouse AlexaFluor 633 and anti-rabbit AlexaFluor
488 conjugated secondary antibodies (ThermoFisher) were prepared at 1:500 dilutions in
PBST and added to their respective wells for 1 hour. After this, the cells were washed an
additional three times with PBS. Upon removal of the separating chamber and polymer
coating, coverslips were mounted onto the slides using Prolong Gold Antifade mountant
with DAPI. Images were collected using a Leica TCS SP8 laser-scanning confocal
microscope.
Stained cells were imaged using either a 488-nm or a 633-nm white light laser with
spectral emission collected between 495–520 nm and 650–750 nm, respectively. The
pinhole was set at 1 Airy unit (53.1 m). The DAPI nuclear stain was imaged using the
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AOTF (405) Ar. Each image was frame and line averaged 4 and 2 times, respectively, at
a scan speed of 8000 Hz. An Apo plan 20X 0.3 NA objective was used. Image analysis
was performed using LAS X and Fiji/Image J software.
4.2.6 Extreme Limited Dilution Assay
An extreme limited dilution assay is a dose-response experiment that allows
quantification of biologically active populations.28 It was employed in this work to
determine the stem cell frequency within small populations of cells as previously
described.29 Briefly, OVCAR-8 and SHIN-3 cells were seeded at densities of 50, 100, 250,
and 500 cells in ultralow attachment 96-well plates. Spheroid formation was monitored
over a period of 21 days. On the 21st day of culture, the number of wells containing a
spheroid were counted. Based on initial cell density, along with number of tested and
positive samples, a measure of the confidence interval for cancer stem cell frequency
was generated using ELDA software provided developed at the Bioinformatics Division
of the Walter and Eliza Hall Institute (WEHI) of Medical Research.
4.3 Results and Discussion
4.3.1 CSC in OC Cell Monolayers
Due to its level of recurrence and subsequent chemoresistance, a considerable
amount research has been devoted to the study of CSCs in ovarian cancer. Therefore, in
this section, the presence of several biomarkers associated with ovarian CSCs, namely,
CD117, CD133, CD44, and ALDHA1, were evaluated in SHIN-3, OVCAR-5, OVCAR-8,
and OVCAR-3 cells. As mentioned earlier, each marker has been associated with
increased self-renewal, tumorigenesis, chemoresistance, and angiogenesis. 1, 6,
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15, 30-31

Through my analysis of OC cell monolayers, it was found that CD117 expression was not
observed in either cell line. Expression of both CD133 and CD44 in OVCAR-5 and
OVCAR-8 cells was observed, while OVCAR-3 and SHIN-3 expressed CD133 and CD44,
respectively (Figure 4.1. A. and B). Both OVCAR-3 and SHIN-3 were found to express
ALDHA1; however, ALDHA1 was observed to have nuclear localization in OVCAR-3 as
opposed to the cytosol for SHIN-3 cells. Expression of ALDHA1 in OVCAR-3 nuclei will
have to be investigated further as it suggests that active enzyme is present. From these
findings and those presented in Chapter 3, it is hypothesized that cells expressing either
CD44 and CD133, or those expressing CD44 in conjunction with ALDHA1, have
increased potential to form spheroids or cell aggregates under conditions that lack a
support matrix. This observation is supported by OVCAR-5 and OVCAR-8 cells being
positive for CD44 and CD133 and forming loose aggregates and spheroids, respectively.
SHIN-3, on the other hand, lacked CD133, but expressed both CD44 and ALDH— both
which have been found to initiate tumor growth in the absence of CD133. 10-11, 13-14
Furthermore, it was noticed that cell lines derived from patients with advanced disease
lacked expression of ALDHA1, which would explain why OVCAR-5, OVCAR-8, and
OVCAR-3 were found to be ALDHA1-negative. In addition, CD44 was observed in
OVCAR-5, OVCAR-8, and SHIN-3, all of which had more aggressive proliferation
patterns. Additionally, the findings presented in Chapters 2 and 3 suggested that
increased proliferation and sphere-forming ability was associated with cell lines that had
increased NQO1 activity. Therefore, CD44 expression may be linked to enhanced NQO1
activity as well. It is plausible that the absence of CD44 and low NQO1 activity may be
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affecting both proliferative and sphere-forming ability in OVCAR-3 cells, despite their
expression of CD133, which has long been associated with tumorigenesis. 30
1.

A.

2.

3.

4.
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Figure 4.1. (A) Western blot analysis of OC cell monolayers against CSC markers in
(1) SHIN-3, (2) OVCAR-5, (3) OVCAR-8, and (4) OVCAR-3. Bands represent 25 g of
protein. -actin was used as an internal standard. (B) ICC/IF images of staining against
CSC biomarkers in OC cell monolayers. Nuclear colocalization was achieved using
DAPI stain.
(Fig. cont’d.)
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4.3.2 CSC in OVCAR-8 and SHIN-3 Spheroids
Although CSC presence in cell monolayers provided insight into the proliferative and
tumorigenic potential of the studied cell lines, determining whether those findings would
hold true within spheroids would be advantageous. As noted in Chapter 3, gene
expression in monolayers is often questionable due to cells lacking the intra-and
extracellular interactions that are often observed in tumors. Thus, CSC presence in
OVCAR-8 and SHIN-3 spheroids was evaluated in bulk culture via western blot.
Consistent expression of CD44 was noticed in 5-day and 12-day old OVCAR-8 and SHIN3 spheroids (Figure 4.2). However, based on the observed western blot band densities,
OVCAR-8 spheroids appear to have enhanced expression of CD44 when compared to
SHIN-3. This increased expression in OVCAR-8 supports findings by Alvero et al., whose
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work suggests that patients with metastatic disease have higher expression of CD44
when compared to tissues derived from patients prior to chemotherapy (i.e., SHIN-3).17
In addition, it was noticed that CD133 was not present in spheroid culture despite being
expressed in OVCAR-8 monolayers. It is speculated that CD133 expression is
downregulated in OVCAR-8 spheroids; however, the cause of this decrease in expression
is unknown. In contrast, the lack of CD133 in SHIN-3 spheroids resembled that for
monolayers in that the protein was not found in bulk samples in either study. These
observations further suggest that CD133 may be upregulated in OC CSCs isolated from
tumor tissues because it assists in tumor formation. However, it may be downregulated
once tumors are established. In contrast, ALDHA1 expression was found to remain
constant in SHIN-3 cells grown as both monolayers and spheroids; these outcomes
indicate that ALDHA1 presence may be necessary for tumor formation and progression.
Also, evaluation of CD117 in OVCAR-8 and SHIN-3 spheroids revealed that CD117 was
not present, which parallels the findings in monolayer culture.
1.

2.

3.

4.

CD117
CD133
CD44
ALDH

-actin

Figure 4.2. Assessment via western blot of cancer stem cell marker presence in
(1) 5-day-old and (2) 12-day-old OVCAR-8 spheroids, and (3) 5-day-old and
(4) 12-day-old SHIN-3 spheroids. Bands are representative of 25 g of protein. -actin
was used as an internal standard.
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4.3.3 CSC Frequency in OVCAR-8 and SHIN-3 Spheroids
Aside from expression of specific CSC-associated biomarkers, the ability of a cell to
initiate tumor formation is another hallmark of stemness in cancer. Non-tumorigenic cells
are thought to comprise the majority of tumor tissues, so researchers have posited that
small populations of tumor-initiating cells within tissues are actually CSCs. In order to
evaluate CSC frequency within a large population of cells, an extreme limiting dilution
assay (ELDA) was performed with OVCAR-8 and SHIN-3 cells. Cells were plated at low
densities (i.e., 50, 100, 250, and 500 cells) in ultralow attachment 96-well plates. After 21
days, the number of wells containing a spheroid were counted, and the frequency of CSC
presence was calculated using ELDA software. In Table 4.3 are shown the number of
spheroids observed at each of the plated densities in addition to the confidence interval
for CSC frequency as determined by the ELDA software. From this data, it was found that
in every 96 OVCAR-8 cells there will be at least one CSC, while in every 130 SHIN-3 cells
there will be one CSC. Based on the obtained confidence intervals, it was determined
that CSC presence in OVCAR-8 is 1.4X more likely to be observed when compared to
SHIN-3 cells plated at the same density.
Table 4.1. The confidence interval of frequency of CSC occurrence in OVCAR-8 and
SHIN-3 cells relative to spheroid formation under attachment-free conditions.
CSC
50 Cells

100 Cells

250 Cells

500 Cells

Frequency

OVCAR-8

90

80

86

79

1/96

SHIN-3

35

77

74

88

1/130
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4.3.4 Phenotypic Evaluation of OC Cell Monolayers
As previously mentioned, CSC are thought to drive EMT in cancer cells. To evaluate
whether an epithelial, mesenchymal, or a mixture of the two phenotypes exists within the
studied cells, western blot (Figure 4.3.A) and ICC/IF (Figure 4.3.B) were conducted.
OVCAR-3 cells displayed a purely epithelial phenotype due to its high expression of
EpCAM and low expression of E-cadherin, which supports previous literature regarding
its phenotypic nature.32 Analysis of OVCAR-8 cells revealed a dominant mesenchymal
phenotype, as evidenced by high expression of vimentin. Additionally, it was the only cell
line to express the mesenchymal marker, N-cadherin, though the latter’s presence is
minimal and only detectable via fluorescence-based techniques. As with OVCAR-3, these
findings are consistent with prior research on OVCAR-8 phenotype.33
While OVCAR-3 and OVCAR-8 were representative of either a highly epithelial or
mesenchymal phenotype, SHIN-3 and OVCAR-5 cells appeared to possess mixed
phenotype, as both epithelial and mesenchymal markers were identified. However, it was
determined that each possessed dominant and recessive expression profiles associated
with each phenotype. SHIN-3 was found to have a dominant epithelial phenotype, as
evidenced by a dense band for EpCAM using western blot, while vimentin was observed
to a lesser degree. ICC/IF corroborated these findings with staining of both EpCAM and
vimentin. On the contrary, OVCAR-5 cells had a dominant mesenchymal phenotype,
because dense bands and highly fluorescent staining of vimentin was observed via
western blotting and ICC/IF, respectively. Moreover, ICC/IF analysis revealed that
OVCAR-5 had low expression of E-cadherin and EpCAM. The presented data supports
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previous findings regarding an intermediate mesenchymal phenotype in OVCAR-5
monolayers.33
Phenotypic characterization of the studied cell lines also reflects their proliferative
abilities detailed in Chapter 2. It can be posited that the increased proliferation rates
recorded in OVCAR-5, OVCAR-8, and SHIN-3 cells are a result of their mesenchymal
characteristics, thus enabling more aggressive growth patterns. Whereas, the highly
epithelial OVCAR-3 cells were less proliferative due to their less invasive phenotype. It
was also observed that spheroid and aggregate formation was closely associated with
cells exhibiting either a mixed or mesenchymal phenotype. Moreover, the presence of a
mesenchymal phenotype or mesenchymal features in OVCAR-8, OVCAR-5, and SHIN-3
further supports the notion that CD44 expression is associated with cells harboring an
aggressive phenotype. Also, CD44 expression was observed in both two-dimensional and
three-dimensional culture systems. In addition, CD133 expression did not appear to be
correlated with epithelial or mesenchymal cells; therefore, it is likely that it is a universal
CSC marker.
A.

Figure 4.3. (A) Western blot analysis of OC cell monolayers against EMT markers in
(1) SHIN-3, (2) OVCAR-5, (3) OVCAR-8, and (4) OVCAR-3. Bands result from analysis
of 25 g of protein. -actin was used as an internal standard.
(Fig. cont’d.)
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Figure 4.3. (B) ICC/IF images of staining against epithelial and mesenchymal
biomarkers in OC cell monolayers. Nuclear colocalization was achieved using a DAPI
stain.
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4.3.5 Phenotypic Heterogeneity in OVCAR-8 and SHIN-3 Spheroids
To examine phenotypic plasticity, bulk protein was extracted from 96 intact spheroids
for western blot analysis. The presence of EMT biomarkers E-cadherin, EpCAM,
vimentin, and N-cadherin were evaluated in each of the spheroids derived from OVCAR8 and SHIN-3 (Figure 4.4.). It was found that OVCAR-8 and SHIN-3 spheroids exhibit a
mixed phenotype, which supports literature regarding tumor heterogeneity.26,
both

E-cadherin

and

EpCAM

were

observed

in

OVCAR-8

34

While

spheroids,

only

E-cadherin was expressed in SHIN-3. In addition, EpCAM expression appeared to
diminish with time as evidenced by the decreased band density in samples extracted from
12-day-old spheroids. Vimentin was also observed in SHIN-3 and OVCAR-8 spheroids
regardless of age, suggesting cells with enhanced motility are present. It was also noticed
that N-cadherin, whose expression was low in OVCAR-8 monolayers, had increased in
spheroid culture. Literature states that upregulation of N-cadherin is often observed in
more aggressive tumor tissues, meaning that in spheroid form, OVCAR-8 is likely more
aggressive than SHIN-3. Interestingly, EpCAM expression dominated SHIN-3
monolayers, while E-cadherin expression was upregulated in SHIN-3 spheroids. It can be
assumed that EpCAM, an adhesion molecule, was highly expressed due to the cells being
grown in monolayer culture.35 While E-cadherin, which is also associated with cell-cell
adhesion, is prevalent in tissue samples, thus leading to is upregulation in
spheroids.24, 26, 36
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Figure 4.4 Analysis of phenotypic heterogeneity in (1) 5-day-old and (2) 12-day-old
OVCAR-8 spheroids, and (3) 5-day-old and (4) 12-day-old SHIN-3 spheroids via
western blot. Bands are representative of 25 g of protein. -actin was used as an
internal standard.

4.4 Conclusions
In sum, it was found that while one or more CSC markers were found to be expressed
in monolayers of each cell line, the same level of expression may or may not be observed
in spheroids. For example, CD133 was present in OVCAR-8 monolayers, but not in
spheroids derived from the cell line. It was astounding that CD133 was not observed in
bulk culture of spheroids because it is a marker that is closely associated with the
formation of tumors.7-8,

37-39

Therefore, it was concluded CSCs have the ability to

upregulate and downregulate CD133 prior to and after formation of spheroids,
respectively. This finding further supports the claim that cancer cells exhibit phenotypic
plasticity in that under different conditions certain genes are upregulated or
downregulated.24, 26, 40 Additionally, due to high expression of CD133 being associated
with tumor formation with and without ALDHA1 being present, it can be concluded that
OVCAR-8 cells have a propensity for spheroid formation that supersedes that of SHIN-3.
The results of the ELDA further support this conclusion because it was found that as little
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as fifty OVCAR-8 cells were capable of producing 2.6X more spheroids than SHIN-3 cells
plated at the same density.
Moreover, based on the formation of spheroids and/or aggregates in OVCAR-8, SHIN3, and OVCAR-5, it was posited that CD44 expression is closely associated with
increased propensity to form tumors in vitro. This finding was further supported by the
lack of spheroid formation in OVCAR-3 cells, in which CD44 expression was
undetectable. Furthermore, both CD44 and ALDHA1 were found to be consistently
expressed in two-dimensional and three-dimensional culture of SHIN-3, while only CD44
was expressed in monolayer and spheroid culture of OVCAR-8. Thus, it was implied that
when the expression of a CSC marker is unaffected by changes in culture format suggest
that it is unique to those cells. Therefore, said CSC marker(s) can be used as a reference
when assessing the expression and activity of enzymes and phenotypic changes within
different samples.
Aside from CSCs, the phenotypic nature of each cell line was examined. It was found
that cells presenting either dominant or partial mesenchymal nature in cell monolayers
were more likely to form spheroids or aggregates under adhesion-free conditions. In
addition, when relating these observations back to the proliferation rates of each cell line
in monolayers the same correlation was found—a mesenchymal phenotype in
monolayers resulted in increased proliferation. As with CSC, the shift from monolayer to
spheroid culture revealed heterogeneity in OVCAR-8 and SHIN-3, with their spheroids
displaying expression of epithelial and mesenchymal markers. The most noticeable shift
in phenotype was observed in OVCAR-8 spheroids, which displayed enhanced epithelial
nature—which was undetectable in monolayers. On the other hand, SHIN-3 continued to
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display a mixed phenotype, but the expression of a different epithelial marker (i.e., Ecadherin) was observed. The degree of phenotypic heterogeneity observed in spheroids
speaks to the plastic nature of the disease. It is likely that co-expression of epithelial and
mesenchymal markers in spheroids is the result of some cells dedifferentiating so as to
reacquire or move toward regaining epithelial functionality, while those harboring only
mesenchymal features scurry to find new areas to invade.
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CHAPTER 5
SUMMARY, CONCLUSIONS, AND OUTLOOK
5.1 Summary
The goal of this research was to investigate tumorigenesis in ovarian cancer using
two-dimensional and three-dimensional cell culture systems as a function of the
expression and activity of cytoprotective enzyme, NQO1, and cell phenotype (i.e., stemlike, epithelial, mesenchymal, or mixed). The expression of NQO1 in four established
ovarian cancer cell lines was characterized in monolayer culture using immunochemical
(i.e., western blot and ICC/IF) and gene expression (i.e., RT-qPCR) techniques. Following
determination of enzyme expression, its activity was quantified using enzyme kinetic
studies and visualized with confocal microscopy using a NQO1-activated fluorescent
probe. Culture-time-dependent proliferation studies were then used to evaluate whether
NQO1 expression and activity were contributing to the proliferative ability of each cell line.
Next, an in vitro tumor model was employed to investigate the propensity of the studied
cell lines to form spheroids under anchorage-independent culture conditions. A detailed
investigation was carried out to determine if the observed expression and activity of the
NQO1 in cell monolayers was correlated with spheroid/aggregate formation. In addition,
NQO1 expression and activity in spheroids were evaluated using western blot, enzyme
kinetics, and probe activation. Finally, an assessment of the cell phenotype in monolayers
and spheroids was conducted using immunochemical techniques (i.e., western blot and
ICC/IF), and the findings of those studies were then reviewed to assess whether they
were linked to NQO1 and spheroid forming ability.
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In the first chapter of this work, it was revealed that increased NQO1 expression and
activity was associated with ovarian cancer cell lines derived from patients prior to
administration of chemotherapy. For instance, the expression of NQO1 was observable
in SHIN-3 and OVCAR-5 cells with western blot; whereas, it was undetectable in
OVCAR-8 and OVCAR-3 cell lines. Similarly, the activity of NQO1 in SHIN-3 and
OVCAR-5 (untreated cell lines) cells was increased compared to that in OVCAR-8 and
OVCAR-3 (treated cell lines). In addition, the NQO1-activated fluorescent probe Q3NTCy
was capable of distinguishing between the studied cell lines as function of their individual
NQO1activity levels, which supported the findings of the enzyme kinetics study that
assessed enzyme activity.
Also, a direct relationship was observed between culture-time-dependent NQO1
activity and proliferation in SHIN-3 and OVCAR-5 cells (i.e., high NQO1 activity and highly
proliferative), and OVCAR-3 cells (i.e., low NQO1 activity and low proliferative ability)
which suggested that changes in NQO1 activity are reflective of number of daughter cells
present at different stages of growth. For example, the highest NQO1 activity and
proliferative ability was observed in SHIN-3 cells, while OVCAR-3 cells had the lowest
activity and proliferative ability. On the other hand, proliferation studies on OVCAR-8 cells
contradicted this trend because they had second highest rate of proliferation after SHIN3, but the measured NQO1 activity for days 3-7 of culture was roughly 5-9X lower than
that of SHIN-3 cells. Despite this noticeable difference in culture-time-dependent NQO1
activity and proliferation in OVCAR-8, it was concluded that relative to OVCAR-3 cells,
each of the remaining cell lines displayed increased NQO1 activity and proliferative ability.
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Next, I sought to determine the ability of each of cell line to produce multicellular tumor
spheroids under growth conditions that did not promote cell attachment to the culture dish
(anchorage-independent conditions). The results of this study were as follows: OVCAR8 and SHIN-3 cells produced compact and semi-compact spheroids, respectively, while
OVCAR-5 cells produced loose aggregates. OVCAR-3 cells did not produce spheroids or
aggregates in this study. It was concluded that cell lines with increased NQO1 activity are
capable of spheroid/aggregate formation. To further support this conclusion, a stable
knockdown of NQO1 was conducted using OVCAR-5 cells. It was found that such NQO1depleted OVCAR-5 cells were neither able to form spheroids, nor achieve the degree of
aggregation observed in wild type OVCAR-5 cells. Also, NQO1 expression was found to
be enhanced in spheroids relative to monolayers in OVCAR-8 based on the presence of
protein bands in western blot studies, whereas such bands were undetectable
monolayers.
In addition, the expression of tumor suppressor p53, which has been shown to be
stabilized by NQO1, was evaluated in each of the cell lines.1-2 It was found that SHIN-3
and OVCAR-8 cells had increased expression of the p53 protein, while expressing low
expression of the p53 gene. In addition, faint p53 protein expression was observed in
OVCAR-3, despite it having the highest expression of the p53 gene compared to the other
cell lines. While an inverse relationship between expression of the p53 gene and protein
was observed in OVCAR-8, SHIN-3, and OVCAR-3 cells, a direct relationship was
observed in OVCAR-5 cells where p53 gene expression was low and subsequent protein
expression was undetectable. After reviewing the findings of the p53 gene and protein
expression study, my initial conclusion regarding the ability of the studied cell lines to form
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spheroids under anchorage-independent conditions held true. Furthermore, my
conclusion was modified so as to highlight that NQO1 activity and proliferative ability
greater than or equal to that observed in OVCAR-8 cells and expression of the p53 protein
greater than or equal to that observed in OVCAR-5 cells was unique to cell lines capable
of spheroid or aggregate formation.
Also, NQO1 activity in day-5 and day-12 SHIN-3 and OVCAR-8 spheroids was
comparable to that of their monolayer formats at day 1 and day 2 of culture. Also, it was
found that the NQO1-activatable probe Q3NTCy enabled visualization of NQO1 activity in
SHIN-3 and OVCAR-8 spheroids in as little as 30-minutes. It was observed that prolonged
exposure (> 30 minutes) to Q3NTCy resulted in increased reporter formation within
spheroids, but due to their thickness, reporter formation at a depth greater than 100 m
into spheroids was not observed. Thus, visualizing all of the active NQO1 in an intact
spheroid using the Q3NTCy probe is not possible.
Another goal of this work was to evaluate the presence of CSCs and cell phenotype
in monolayer and spheroid cultures of the previously mentioned cell lines. The findings of
these studies were then examined to determine whether they could be related to
outcomes from the previously discussed NQO1 studies. Initially, the presence of four CSC
markers (i.e., CD117, CD133, CD44, and ALDHA1), which have been previously
associated with tumor initiation in ovarian cancer, were investigated in cell monolayers by
western blot and immunocytochemistry.3-10 It was found that of the four markers, only
CD133, CD44, and ALDHA1 were present in one or more of the cell lines in this study.
Specifically, it was observed that CD133 was highly expressed in monolayers of OVCAR8, OVCAR-5, and OVCAR-3 relative to SHIN-3. However, upon examination of spheroid
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cultures, CD133 expression was no longer observed for spheroids of OVCAR-8. It was
concluded that increased CD133 expression may be necessary for initiation of spheroid
formation, but it may be downregulated once the spheroid is formed. CD44 was found to
be expressed in monolayers of SHIN-3, OVCAR-5, and OVCAR-8, but not in those of
OVCAR-3. This observation served as yet another noticeable distinction between
OVCAR-3 cells and the other cell lines, which displayed increased NQO1 activity and
proliferative ability in addition to spheroid/aggregate forming ability.
Furthermore, when comparing CD44 presence in SHIN-3 and OVCAR-8 monolayers
to that of their spheroids, it is found that CD44 expression remained constant. Therefore,
not only does CD44 impact spheroid formation, but its constant expression in monolayers
and spheroids. The last CSC marker evaluated was ALDHA1. ICC/IF analysis revealed
that only SHIN-3 and OVCAR-3 cell monolayers contained ALDHA1, but the localization
of the enzyme was different. Specifically, ALDHA1 was observed in the cytosol of SHIN3 cells, but it was found in the nucleus of OVCAR-3 cells. Because the enzyme is primarily
localized in the cytosol, its presence in the nucleus a cell is surprising; thus assessment
of active ALDHA1 enzyme in nuclei should conducted.4 Aside from this, it was observed
that co-expression of ALDHA1 and CD44 (i.e., SHIN-3) or CD44 alone (i.e., in OVCAR-8
and OVCAR-5) will result in spheroid or aggregate formation, which implies that these
CSC markers have a significant role in disease progression and survival.
Aside from CSC presence, I also evaluated the phenotypic nature of each cell line—
specifically by evaluating the expression of biomarkers associated with the epithelial-tomesenchymal transition (EMT), which has been linked to tumor formation. 11-13 It was
determined that monolayer cultures of OVCAR-8 cells presented a purely mesenchymal
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phenotype (i.e., only expression of Vimentin and N-cadherin detected), while OVCAR-3
was purely epithelial based on observed expression of both EpCAM and E-cadherin. On
the contrary, co-expression of epithelial and mesenchymal markers was observed in
monolayers of OVCAR-5 and SHIN-3 cells, with the former exhibiting a dominant
mesenchymal nature and a dominant epithelial phenotype in the latter. This conclusion
stemmed from ICC/IF being capable of detecting low and high levels of EMT markers in
both cell lines, but only those with enhanced expression being detected by western blot.
In transitioning from monolayer to spheroid culture, it was found that OVCAR-8 and SHIN3 spheroids possessed epithelial and mesenchymal characteristics. This observation was
surprising for OVCAR-8 spheroids, because neither epithelial marker was detected in
monolayers, yet both were present in spheroids. Therefore, it was concluded that as with
studies of NQO1 in monolayers and spheroids, protein expression in one culture system
may not dictate whether that protein is expressed in a different culture model.
5.2 Conclusions and Outlook
The work detailed in this dissertation demonstrates the role of NQO1 in spheroid
formation and cell phenotype in four human ovarian cancer cell lines. In addition, the
influence of the enzyme on the proliferative ability of was also assessed. It was concluded
that SHIN-3, OVCAR-5, and OVCAR-8 cells possessed enhanced NQO1 activity, were
highly proliferative, and capable of spheroid/aggregate formation under anchorageindependent conditions. Further analysis revealed that while cancer stem cell markers
were expressed in each cell line, CD44 presence was unique to OVCAR-5, SHIN-3, and
OVCAR-8 cells in monolayers. In addition, a mixed or mesenchymal phenotype was
observed in cell lines that expressed CD44. Therefore, it was concluded that expression
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of cancer stem cell marker CD44, a mixed or mesenchymal phenotype, and enhanced
NQO1 activity relative to OVCAR-3 cells provides a basis for spheroid/aggregate
formation in vitro. In addition, cells possessing the aforementioned characteristics were
found to be highly proliferative in monolayer culture. Figure 5.1 below was constructed to
illustrate major findings in this work.

Figure 5.1. Visual representation of research findings.

The work presented in this document has the potential to serve as a template for
characterizing cancer stem cells as a function of presence and the activeness of diseaseassociated enzymes because it could result in the development of new diagnostic and
therapeutic targets. However, it is imperative that variations in the expression of cancer
stem cell biomarkers between in vitro (i.e., traditional monolayer and anchorage
independent/dependent spheroid culture), in vivo (i.e., mouse models), and ex-vivo (i.e.,
biopsied samples) systems are identified, so as to give researchers a better depiction of
which models are suitable for evaluation of cancer cells. The rationale is based on it being
reported that gene expression profiles in cell monolayers are not entirely reflective of what
is observed once those cells are cultured spheroid models or in vivo.14-15 Based on the
findings presented in this dissertation, the expression of some cancer stem cell markers
is not always affected by different culture conditions. Therefore, it is beneficial to assess
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the expression and activity of enzymes present in cells that express said CSC markers.
This would be advantageous for drug developers because constantly expressed CSC
markers can serve as internal positive control or calibrator genes when comparing
significant changes in gene expression of target molecules in samples, prior to and after
treatment with anticancer agents or radiation therapy.
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